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Abstract

A flow-through enzyme-linked immunosorbent assay was developed based on affinity
chromatography using the determination of ferritin in serum as a model system. In
this method, samples and standards are introduced to separate columns containing
immobilised anti-ferritin antibody, and antigen bound by solid-phase antibody is
subsequently detected using an anti-ferritin-alkaline phosphatase conjugate. To detect
immobilised label, p-nitrophenyl phosphate is added and product is developed in the
column at room temperature. Following elution of product from the column, the
absorbance is measured and the columns are regenerated using a low pH elution.
The final developed system requires approximately 1.5 h for the simultaneous assay of
standards and up to forty samples. The lower limit of detection using a 200 pi assay
volume is 1.82 x lO '^ mol or 9.11 x 10 ‘^ mol/l (4.1 pg/l). HoM>ever, there is potential
to increase the assay sensitivity further through the use of amplification .systems for
alkaline phosphatase label. In addition, the pre.sent assay gives accurate results, good
precision, and is easy to perform. The immunoaffinity columns have been shown to be
stable for at least ten assays and presumably could be used for an even greater
number. By using different immobilised and labelled antibodies, this method could
easily he adaptedfor use with other analytes.
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1 Introduction

1 Introduction

Quantitative and qualitative methods using antibodies or antigens as primary reagents
are now integral to many clinical, pharmaceutical, and basic scientific investigations.
Such popularity arises either because they are the most effective and suitable of the
methods available or because no other type of assay system is feasible. A diverse array
of formulations exists, many of which are the subject of discussion in this review.

1.1 Naming Immunoassays

The nomenclature of immunoassays varies greatly, reflecting the immense diversity of
assay formulations. Most assay names contain the combining word innmino, indicating
the assay is antibody-antigen based, another combining word indicating the type of
label used {enzyme or enzymo, radio, flnoro, etc.), along with the word assay
(Gosling, 1994). Examples include radioimmunoassay (RJA), enzyme immunoassay
(EIA), and fluoroimmunoassay (FIA).
These names usually refer to limited-reagent competitive immunoassays, whereas
reagent-excess assays are commonly distinguished by reversing the order of the
combining forms, e g., immunoradiometric assay (IRMA), immunofluorometric assay
(IFMA), and immunoenzymometric assay (lEMA) (Gosling, 1994).
Enzyme-linked immunosorbent assay (ELISA) is a term used to describe solid-phase
immunoassays incorporating enzyme as label, irrespective of whether the assay is
competitive or non-competitive.

1.2 Classification of Immunoassay

Immunoassays may be classified according to the type of analysis, test sample, assay
system, and assay conditions (Miyai, 1991). Table 1.2.1 outlines the criteria that may
be used in immunoassay classification.

Table 1.2.1 Classification of immunoassay
Type of Analysis
Quantitation

v

Characterisation
(epitope mapping)

(semi-quantitative, qualitative)

Test Sample
Antigen

v

(macromolecule, peptide, hapten)

Antibody
(antibody to exogenous antigen,
autoantibody)

Assay System
Labelled

v

Unlabelled

Competitive (limited-reagent)

v

Non-competitive (reagent-excess)

Separation (heterogeneous)

v

Non-separation (homogeneous)

Visual assessment

v

Instrumentation

Assay Conditions
Liquid phase

v

Solid phase

Equilibrium

v

Non-equilibrium

Manual

v

Automated

(Modified from Miyai, 1991)

While all these factors could potentially be used to classify immunoassays, authors tend
only to exploit the differences in assay systems when categorising methods. For
example, reviews dealing specifically with enzyme immunoassay (Blake and Gould,
1984; Oellerich, 1984) divided assays on the basis of whether they required a

separation step (heterogeneous) or not (homogeneous). They further divided the two
groups into competitive and non-competitive assays, where applicable. Porstmann and
Kiessig (1992) discussed enzyme immunoassays in three groups, the two-site enzyme
immunoassay for macromolecular antigen detection, the homogeneous enzyme
immunoassay, which was divided further into competitive and non-competitive
methods, and immunoassays for specific antibodies. Surprisingly, the competitive
ELISA for antigen was not accommodated by this classification. Gosling (1990)
devised a six group classification from the publications appearing in Clinical Chemistry
between 1980 and 1990 using the type of assay system and test sample as his criteria.
For example, groups 1 to 4 and 6 are mainly assays of macromolecular antigens or
haptens, while group 5 assays are for specific antibodies. Assays in group 4 and most
assays in groups 3 and 5 involve the use of excess reagents, whereas those in groups 1
and 2 involve limited reagent concentrations, particularly limited antibody. Group 6
assays can make use of either limited or excess reagents in homogeneous format.

Group I includes immunoassays of macromolecular antigens and haptens, in which
labelled analyte is used. They involve the use of limited concentrations of antibody and
are universally termed competitive immunoassays.

Group 2 assays make use of limited concentrations of labelled antibody and
immobilised analyte in the measurement of macromolecular antigens and haptens
(competitive).

Group 3 assays include precipitation, nephelometric, and turbidimetric immunoassays,
as well as particle agglutination and particle-counting immunoassays. In general, the
endpoints involve a direct detection of immune complexes and some are characterised
by the lack of any labelled reagent.
3

Group 4 includes assays involving labels, in which all the principle reagents are in
excess (non-competitive).

Group 5 incorporates assays for quantifying specific antibodies, while group 6 includes
methods not requiring separation steps (homogeneous). They have features in common
that result in a modulation of the signal from label by the binding reaction.

For simplicity, labelled immunoassays can be divided into two large groups,
homogeneous or heterogeneous, with each group capable of further division into non
competitive and competitive methods. The term competitive indicates that the analyte
(hapten, macromolecular antigen or antibody) is in direct competition with another
molecule for binding to an antigen or antibody. Immunoassays relying on the direct
detection of immune complexes (e g., turbidimetry and nephelometry) can be treated
separately.

1.3 Heterogeneous Immunoassays

Immunoassays requiring bound from free label separation.

1.3.1 Competitive (limited-reagent)
The category includes the classical competitive immunoassay for macromolecular
antigens and haptens (Figure 1.3.1), in which the analyte competes with a labelled
analyte for a limited number of antibody binding sites (Osterman et al., 1979; Rappuoli
et al., 1981, Kaibe et al., 1990; Luppa et al., 1995; Munro and Stabenfeldt, 1984,
Veneziale et al., 1981). Following an incubation step, antibody-bound label and free
label are separated to allow one of them to be quantified, usually the bound. Plotting
the concentration of analyte against the signal obtained gives an inverse plot if bound
label is measured or a direct relationship if one measures the free fraction. The labelled
analyte is not necessarily identical to the analyte being analysed, but it must be able to
compete with the analyte for sites on the antibody (Luppa et al., 1995). Generally,
limited concentrations of labelled analyte are used, however, to lower the detection
limit, one may add the label in excess some time after the mixing of analyte and
antibody (Gosling, 1990). This has the effect of promoting disequilibrium, giving an
instantaneous titration of binding sites unoccupied by analyte (Gosling, 1990).
Antibodies of a particular isotype can also be measured in a competitive format using a
labelled antibody in competition for a limited number of sites on solid-phase anti
isotype immunoglobulin

(Engvall

and

Perlmann,

1971).

Also,

heterogeneous

competitive assays can detect specific antibodies independently of their isotype using
enzyme-labelled specific antibodies and antigen immobilised on solid phase (Porstmann

and Kiessig, 1992). However, the sensitivity of these assays is limited greatly by the
affinity of the antibody to be detected (Porstmann and Kiessig, 1992).

Analyte from sample
Antibody bound to
analyte from sample
Limited amount
of antibody

Labelled analyte

Antibody bound to
labelled analyte

Either free or bound label measured

Figure 1.3.1 Classical competitive immunoassay for macromolecular antigen and
hapten. All components are mixed with a limited amount of antibody specific for
analyte. Separation of hound from free label is necessary before the measurement of
either.

Other competitive immunoassays exist which use a limited concentration of labelled
antibody and immobilised analyte in the measurement of macromolecular antigen
(Ogbonna et al., 1995) and hapten (Sturgess et al., 1986). These assays have the
advantage that labelled antigens with, for example, low solubility in aqueous media can
be avoided. Immobilised analyte competes with free analyte in the sample for a limited
number of binding sites on the labelled antibody in solution (Figure 1.3.2). To ensure
that immobilised analyte is present in a constant limited amount in each assay vessel,
the analyte is coupled to a protein and this is used to coat the solid phase. Ogbonna et

al. (1995), in an assay for apolipoprotein BlOO (apoB), used an apoB-rabbit
immunoglobulin conjugate in competition with apoB in sample for binding to
acridinium N-hydroxysuccinimide-labelled anti-apoB antibody. Goat anti-rabbit IgG,
immobilised to magnetic particles, was used to separate the apoB-rabbit IgG conjugate
bound to labelled antibody from labelled antibody bound to apoB from the sample.
Bound chemiluminescence was measured, giving an inverse calibration curve.

Analyte from sample

Labelled antibody bound to
analyte from sample

Limited amount of
labelled antibody

1

Fraction measured

Labelled antibody bound to
immobilised analyte

Limited amount of
solid-phase analyte

Figure 1.3.2 Competitive immunoassay for macromolecular antigen and hapten using
a limited amount of immobilised analyte and labelled antibody. After washing, the
label associated with solid phase is measured.

Thompson et al. (1985) developed an interesting competitive immunoassay for
adenosine deaminase binding protein (ABP), which differs slightly from those
mentioned above. The method uses a biotin-labelled anti-idiotype antibody in
competition with ABP for a solid-phase monoclonal antibody (URO-4), which is
capable of recognising ABP and being recognised by the biotin-labelled antibody.
When no ABP is present in sample, binding of the biotinylated anti-idiotype antibody is

7

maximal, which is then detected using an avidin-horseradish peroxidase conjugate.
Increasing ABP decreases the binding of the anti-idiotype antibody to URO-4, thus
decreasing the amount of bound enzyme.

1.3.2 Non-competitive (reagent-excess)
The category includes the one-site immunoassay for haptens, which employs a
moderate excess of labelled antibody incubated with sample, followed by an excess of
immobilised hapten to remove unreacted labelled antibody (Miles and Hales, 1968;
cited in Piran et al., 1995). The signal associated with the supernate is measured after
transfer to a second reaction cuvette, giving a direct relationship (Figure 1.3.3). Piran
et al. (1995) applied this principle to the measurement of triiodothyronine (T3) using a
chemiluminescent label. Acridinium ester (AE)-labelled anti-T3 is incubated with
sample, producing AE-anti-T3/T3 complexes. Unreacted AE-anti-T3 is removed using
an excess of controlled-pore glass particles (CPG) with immobilised diiodothyronine
(T2). Only AE-anti-T3 possessing two unoccupied sites is bound by the T2-coated
CPG. Paramagnetic particles (PMP) with immobilised anti-AE are then added to the
same cuvette to capture AE-anti-T3/T3 complexes. AE-anti-T3 immobilised to the CPG
cannot bind due to steric hindrance. The PMP are magnetically separated from the
CPG and the chemiluminescence associated with the PMP is measured, giving a direct
relationship. The authors stressed that this system has advantages over previous onesite assays, since there is no need to transfer material to a new cuvette and the label is
measured in the absence of possible sample interferences.

Labelled antibody bound to analyte

Step 1
Step 2

Excess amount of
solid-phase analyte

Free labelled antibody
removed by immobilised
analyte

Excess of labelled
antibody

Figure 1.3.3 One-site immunoassay for haptens. Analyte from sample is reacted with
an excess of labelled antibody (step 1). To remove unoccupied labelled antibody, an
excess of solid-phase analyte is added (step 2). The signal associated with the
supernate is measuredfollowing transfer to a new reaction vessel.

The category also includes the two-site sandwich immunoassay for macromolecular
antigens, in which an excess of solid-phase antibody captures analyte in solution, with
subsequent detection using an excess of antibody-label (Figure 1.3.4) (Ishikawa et al.,
1980; Papoian et al., 1991; Noe et al., 1992; Masayuki et al., 1993). Therefore, signal
obtained is directly proportional to the amount of analyte present in the sample. While
this type of assay format is generally used for the measurement of macromolecular
antigens, it has also been used to measure human IgE using goat antibodies as capture
and label (Ruan et al., 1987). Generally, two-site assays involve the sequential
incubation of sample and labelled antibody, but one-step assays involving simultaneous
incubations have been developed (Nomura et al., 1983; Burgi et al., 1988; Tanebe et
al., 1992; Brailly et al., 1994). However, the high-dose hook effect becomes
problematic in these systems, since at high analyte concentrations there is competition
between free analyte and conjugate-bound analyte for reaction with the solid-phase
antibody (Nomura et al., 1983; Porstmann and Kiessig, 1992). Theoretically, but not
practically, the problem may be avoided through the use of a large amount of

immobilised and labelled antibody (Nomura et al., 1983). Otherwise, one may use the
sample to be tested in two dilutions differing from each other by at a least factor of 100
(Nomura et al., 1983; Porstmann and Kiessig, 1992). If speed of assay is not a priority
and sensitivity is, one may use an unlabelled secondary antibody to detect the
immobilised analyte, followed by a anti-species conjugate. Ko et al. (1992), in an assay
for human interleukin (IL)-8, used a mouse monoclonal antibody as primary capture,
rabbit anti-lL-8 as the secondary antibody, and an alkaline phosphatase-labelled goat
anti-rabbit antibody as conjugate. To prevent cross-reaction, it is important that the
primary capture antibody and the secondary antibody are derived from different
species.

Analyte from sample
Excess of
immobilised antibody

Solid-phase antibodyanalyte complex

Excess of labelled
antibody
Labelled antibody attached to solid pha.se via
analyte from sample

Figure 1.3.4 The principle of the two-site sandwich assay for macromolecular
antigen. Antigen in the sample is mixed with an excess of solid-phase antibody. Afterwashing the solid phase, labelled antibody is added and label remaining bound after
washing is measured.

Heterogeneous non-competitive immunoassay is also used for the measurement of
specific antibodies. In the “antibody capture” assay (Figure 1.3.5), serum is incubated
with an excess of solid-phase antigen and the amount of bound antibody is detected
using an excess of labelled class-specific antibody (Chlang et al., 1989).
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Excess of immobilised antigen

Specific antibody
from sample

Immobilised antigenanhbody complex

Excess of labelled
class-specific antibody
Specific antibody “sandwiched” between
immobilised antigen and labelled classspecific antibody

Figure 1.3.5 “Antibody capture” immunoassay for specific antibody of particidar
isotype. Antibody in sample is mixed with an excess of solid-phase antigen. After
washing, an excess of labelled anti-class antibody is added. Signal from bound
antibody is measured after washing.
“Antigen capture” assays (Figure 1.3.6) use immobilised anti-class antibodies directed
against relevant antibodies from the sample (Gosling, 1990). Subsequently, labelled
antigen is captured only by the immunoglobulin of interest or one may use unlabelled
antigen, which can be detected through the use of a labelled antibody directed against
the bound antigen (Gosling, 1990).

Excess of immobilised
anti-class antibody

Antibody of specific
class from sample

Antibody from sample bound to
solid-phase antibody

Specific antibody detected
by labelled antigen

Excess labelled antigen

Figure 1.3.6 “Antigen capture” immunoassay. Antibody of particular class from
sample is bound by excess of solid-phase anti-class antibody. After washing, specific
antibody is detected using labelled antigen added in excess. Signal associated with
solid phase is measured after a washing step.

1.4 Homogeneous Immunoassays

Homogeneous immunoassays do not require bound from free label separation. Assays
in this category generally rely on a modulation of the signal from the label by the
antigen-antibody reaction. However, separation-free immunoassays are generally less
sensitive than their heterogeneous counterparts (Gosling, 1990), with detection limits
ranging from 10'^-10'^' mol/l (Jenkins, 1992; Price and Newman, 1991). This is largely
due to signal measurements in the presence of potential sample interferents (Jenkins,
1992). In any case, the assays tend to be used to monitor concentrations of analytes
such as drugs when low detection limits are not required.

1.4.1 Competitive

1.4.1.1 Enzyme multiplied immunoas.say lechnicfue (EMIT)
Rubenstein et al. (1972) developed the first homogeneous enzyme immunoassay,
which relied on the modulation (inhibition) of enzyme activity of a morphine-lysozyme
conjugate when bound by anti-morphine antibodies. Addition of free morphine to this
mixture reduced the inhibition of enzyme activity in direct proportion to the amount of
morphine added (Figure 1.4.1). The small size of some haptens permits intimate
interaction of the antibody and enzyme within the complex, thus providing a
mechanism for modulation of enzyme activity through steric exclusion (Rubenstein et
al., 1972). By contrast, this is more difficult to achieve using enzyme conjugates of
large molecules, unless the substrate is sufficiently large. Gibbons et al. (1980)
employed the same principle to the assay of IgG antibodies using an lgG-|3galactosidase conjugate in competition with IgG for sites on rabbit anti-human y-chain
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antibodies. The commonly used substrate, r)-nitrophenyl-[3-galactoside (oNPG), was
coupled via the o-nitrophenyl group to high molecular weight polymers (dextrans),
producing macromolecular substrates required (10-2,000 K). When a conjugate with
4.3 IgG’s per enzyme was incubated with excess rabbit anti-human IgG, the activity
with 0.4 mmol/1 10 K, 40 K, 70 K, and 2,000 K substrates was inhibited by 42, 83, 87,
and 95%, respectively.

E

Analyte from sample
+

Antibody bound to
analyte from sample

Limited amount
of antibody

Product

rwi
Substrate—

Enzyme-labelled
analyte

Antibody bound to labelled
analyte inactivates enzyme
activity

Figure 1.4.1 Principle of the EMIT system of homogeneous enzyme immunoassay.
Conjugation of hapten or macromolecular antigen does not destroy enzyme activity,
hut combination with specific antibody causes a marked inhibition. The measured
enzyme activity is dependent on the relative amounts of free analyte and enzymelabelled analyte.

It is also possible to observe an increase in enzymatic activity upon antibody binding.
Thompson (1989; cited in Jenkins, 1992), in an assay for thyroxine (T4), used a
conjugated ligand which was the inhibited form of malate dehydrogenase. Binding of
antibody resulted in the reversal of enzyme inhibition.
13

In addition to the use of enzymes as labels, prosthetic groups (Morris et al., 1981),
substrates (Burd et al., 1977, Wong et al., 1979), inhibitors (Bacquet and Twumasi,
1984; Finley et al., 1980), and enzyme fragments (Khanna et al., 1989; Engel and
Khanna,

1992)

have been

conjugated

to

ligands

in

homogeneous

enzyme

immunoassay.

1.4.1.2 Prosthetic gi^oup-lahelled immunoassay (PGLIA)
Morris et al. (1981) designed a homogeneous competitive immunoassay for
theophylline using FAD as label. In this system, sample ligand and FAD-labelled ligand
compete for sites on antibody of limited concentration. In the free form, the ligandFAD conjugate has the ability to regenerate the active holoenzyme, glucose oxidase,
but when bound by antibody it is sterically restricted from associating with apoenzyme.
Therefore, glucose oxidase activity is at its lowest when no ligand is present in the
sample.

1.4.1.3 Reactant-labelled fluore.scent immunoassay (RLFIA)
Homogeneous methods using substrate or reactant as label have also been described
(Burd et al., 1977; Wong et al., 1979). The hapten is labelled with a fluorogenic
substrate, (3-galactosyl umbelliferone, which is not fluorescent under assay conditions.
The hapten/dye conjugate is used as substrate for the enzyme P-galactosidase,
generating the fluorescent product, umbelliferone. In the absence of hapten in sample,
the conjugate is bound by specific antibody, sterically restricting access of the enzyme
to substrate and little fluorescence results. Fluorescence increases in direct proportion
to the added hapten. Worah et al. (1981) developed an assay for human IgM using the
same principle with N-(6-aminohexyl)-7-|3-galactosyl-coumerin-3-carboxamide as
fluorogenic substrate. This type of scheme is limited in that it lacks the amplification
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feature of other enzyme-based immunoassays, since the system produces only one
product molecule per label. Therefore, its detection limit is dependent upon the
detection limit of the fluorescent product.

/. 4.1.4

hihibitor-lahelled immunoassays

Irreversible inhibitors have also been used as labels in the development of
homogeneous immunoassays (Bacquet and Twumasi, 1984; Finley et al., 1980).
Bacquet and Twumasi (1984) used an avidin-5,5-diphenylhydantoin (DPH) conjugate
in competition with free DPH for a limited number of antibody binding sites. The
interaction of anti-DPH with the avidin-DPH conjugate sterically inhibits avidin
inactivation of pyruvate carboxylase. Therefore, when the DPH hapten is absent from
sample, the avidin-DPH conjugate is bound by antibody and enzyme activity is
maximal. The activity decreases with increasing DPH, i.e., an inverse relationship
exists.
The same rationale was applied to an assay for T4 using a cholinesterase inhibitor as
label (Finley et al., 1980).

1.4.1.5 Cloned enzyme donor immunoassay (CEDIA)
This elegant homogeneous immunoassay system uses enzyme fragments prepared by
recombinant DNA technology (Khanna et al., 1989; Engel and Khanna, 1992). Two
separate genes are engineered to produce two separate polypeptide fragments, enzyme
donor (ED) and enzyme acceptor (EA), which can come together to produce active (3galactosidase enzyme. The ED can be coupled to ligands without affecting the activity
after complementation. If the hapten-ED component is bound by antibody, the
recombination process cannot occur and so enzyme activity is lost. The system is
typically competitive, with hapten-ED and hapten in sample competing for limited
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antibody. When hapten is absent, binding of conjugate is maximal and the hapten-ED is
unavailable to bind with EA. With increasing free hapten, the hapten-ED is available to
combine with the EA fragment, resulting in an active enzyme and an increase in signal.
CEDI A assays have been successfully developed for theophylline, phenobarbitol, B12,
and folate, as well as large molecular weight analytes like ferritin (Engel and Khanna,
1992).

1.4.1.6 Fluorescence-based homogeneous immunoassay
Fluorescent labels may also be used in homogeneous competitive immunoassay formats
for haptens, macromolecular antigens, and antibodies. As with enzyme-based assays,
signal is modulated as a result of the binding reaction. Methods include fluorescence
polarisation immunoassay (Young et al., 1984; Sidki et al., 1988), fluorescence
quenched immunoassay (Kobayashi, 1980; Nargessi et al., 1979), and the fluorescence
excitation transfer immunoassay (Van der Werf and Chang, 1980; Calvin et al., 1986).
The fluorescence quenched assays in the “direct” format are used for haptens, whereas
the “indirect” method can be used for both macromolecular antigen and antibody.
Fluorescence excitation transfer is useful for all analytes.

1.4.2 Non-competitive
The category includes the enzyme channelling immunoassay (Litman et al., 1980),
enzyme enhancement assay (Gibbons et al., 1981), and liposomal immunoassay (Frost
et al., 1996).

1.4.2.1 Enzyme channelling immunoassay
The assay allows for the quantitation of large antigens and antibodies using a specific
hexokinase-labelled antibody and agarose beads; the latter is coated with specific
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antibody and glucose-6-phosphate dehydrogenase. The subsequent binding reactions
result in an accelerated formation of NADH from glucose, ATP, and NAD due to the
close proximity of the two enzymes. By contrast, there is a pronounced lag phase in
the reaction when the enzymes are separated. The assay measures the rate of NADH
formation fluorometrically and gives a direct relationship.

1.4.2.2 Enzyme enhancement immunoassay
Gibbons et al. (1981) designed the enzyme enhancement assay for polyvalent ligands
and antibodies. A limited amount of |3-galactosidase-labelled antibody combines with a
polyvalent analyte and then an excess of negatively charged antibody is added. The
binding of the second succinylated antibody in excess increases the local charge around
the enzyme, directly affecting the rate of formation of product from dextran-linked
oNPG Product manifests itself by forming a second light scattering phase, in the form
of small droplets, which can be determined by turbidimetry. The relationship is direct
and has been used for the measurement of human IgG and C-reactive protein (CRP).

1.4.2.3 Liposomal immunoa.s.say
Liposomes entrapping the dye sulphorhodamine were used to develop an assay for
anti-cardiolipin antibodies (AC As) (Frost et al., 1996a). IgG AC As induce liposomal
lysis in the presence of magnesium ions and the resulting absorbance changes are
directly proportional to the amount of ACAs present. The dye, when trapped in the
liposomes, forms dimers at high concentrations which absorb at 530 nm. When
released from the liposomes into aqueous media, the absorption spectrum reverts to
that of the free dye (565 nm). Therefore, one can monitor the decrease in absorbance
at 530 nm (inverse) or increase at 565 nm (direct).
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1.4.2.4 Substrate inhibition immunoassay
Suzuki et al. (1989) developed a homogeneous enzyme immunoassay for protein C, in
which aggregation of the enzyme label overcame substrate inhibition by H2O2. The
assay uses horseradish peroxidase-labelled antibody to produce aggregates with protein
present in sample. These aggregates have peroxidase activity in the presence of excess
H2O2, whereas free labelled antibody does not. Therefore, the relationship between
protein C concentration and enzyme activity is direct.
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1.5 Immunoassays Relying on Direct Detection of Immune Complexes

The

category

includes

immunodififlision,

nephelometric,

and

turbidimetric

immunoassays, as well as particle-aided immunoassays. These systems make use of
labelled and unlabelled reagents, and involve the direct detection of immune
complexes.
Single radial immunodiffusion (SRID) involves pipetting a volume of sample into holes
cut into a buffered agar gel containing specific antibody and, after incubation,
measuring the diameter of precipitin rings visible around each well, the diameter being
directly proportional to the amount of analyte present (Salabe et al., 1996). “Rocket”
electrophoresis is based on the same principle, however, the time of reaction is reduced
significantly through the use of electric charge (Nunez et al., 1997). Peaks or rockets
form in the gel, the height of which are directly proportional to the concentration of
analyte present.
More refined approaches used to monitor immune complex formation are turbidimetry
(Weets et al., 1996) and nephelometry (Pernet et al., 1996). The principles of light
scattering

techniques

such

as

turbidimetry

and

nephelometry

are

discussed

comprehensively by Price et al. (1983). Nephelometry measures the scattering species
(immune complexes) in solution by a means of the increase in light intensity at some
angle 0 when the incident beam is passed through the sample (Figure 1.5.1a). The
angle is usually 90°, but some nephelometers are designed to measure scattered light at
an angle other than 90°, in order to take advantage of the increased forward scatter
intensity caused by high scattering from larger particles (immune complexes). When
light scatter units are measured and plotted against known concentrations of analyte,
the relationship is non-linear. Turbidimetry, on the other hand, measures the scattering
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species in solution by means of a decrease in intensity of the incident beam as it passes
through the sample (Figure 1.5.1b). Light has been lost due to reflection, absorption,
and scatter. Linear standard curves are used in turbidimetry to convert transmittance to
concentration, giving inverse plots.

A.

B.

If

TLight source

Detector

Light source
Absorption, reflection, scatter
Detector

Figure 1.5.1 Principles of nephelometry (A) and Uirhidimetry (B).

To increase the sensitivity of immune complex detection,

turbidimetry and

nephelometry can also be carried out using labelled antibody or antigen in particleenhanced immunoassays. The particle-enhanced turbidimetric immunoassay (PETIA)
and the particle-enhanced nephelometric immunoassay methods have both been used to
measure protein antigens using antibody-coated latex particles (Medcalf et al., 1990a;
Medcalf et al., 1990b; Borque et al., 1993; Borque et al., 1995). Antibodies have also
been measured using either antibody coated particles (Thakkar et al., 1991) or particles
coated with specific antigen (Harchali et al., 1994).
Particle-aided immunoassays of this type (direct agglutination) are suitable only for the
measurement of antibody and multivalent antigen, since haptens may not allow immune
complex formation with bivalent antibody. However, particle-enhanced inhibition
assays (turbidimetric and nephelometric) have been developed using analyte-coated
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particles in competition with analyte from sample for antibody binding sites. This
format is particularly useful for haptens, since numerous hapten molecules can coat the
solid-phase particle, thus each particle is essentially acting as multivalent antigen.
Resultantly, immune complex formation with bivalent antibody is made possible. Such
assays have been used in the measurement of small molecules such as digoxin (Davey
et al., 1997) and theophylline (Litchfield et al., 1984), as well as albumin (Thakkar et
al., 1997), alpha lactalbumin (Cuilliere et al., 1997), and immunoglobulins G, A, and M
(Cuilliere et al., 1991).
Particle-counting immunoassay (PACIA) differs slightly in that it involves measuring
the decrease in number of unagglutinated particles during the course of an
immunoreaction (Masson and Holy, 1986; Mathieu et al., 1989; Collet-Cassart et al.,
1981). This type of light scattering immunoassay appears to be the most sensitive,
giving detection limits in the picomolar range or lower, e.g., 1.5 pmol/1 (Mathieu et al.,
1989), 0.2 pmol/1 (Wilkins et al., 1988; cited in Gosling, 1990).
Generally, immunoassays relying on direct detection of immune complex formation
have to use polyclonal antisera, since monoclonal antibodies alone cannot precipitate
antigen unless it has multiple repeating epitopes. However, mixtures of monoclonal
antibodies can be used to assay macromolecular antigens (Mathieu et al., 1989).
Moreover, single monoclonal antibodies can be used in inhibition formats for hapten
and macromolecular antigen, since numerous molecules of analyte are coupled per
particle (Davey et al., 1997; Thakkar et al., 1997).
In addition, to maximise and accelerate precipitin formation in light-scattering
immunoassays, polyethylene glycol 6,000 and 8,000 may often be used (Litchfield et
al., 1984; Collet-Cassart et al., 1981; Thakkar et al., 1997).
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Red blood cells have also been used as labels in direct detection immunoassays, for
example, chicken or sheep red cells coated with Treponema pallidum antigen are used
in the haemagglutination test for detection of specific antibody (Kasahara, 1992).
Presence of antibody in patient serum gives visible agglutination of the red cells
(haemagglutination). Dilution of patient serum allows one to titre the antibody.
Haemagglutination tests are now available in kit form for detecting rheumatoid factor
and antibody to hepatitis B virus (HBV) surface, e, and c antigens.
Latex particles have also been used in simple agglutination assays for, for example,
human

chorionic

gonadotropin

(hCG),

fibrin

degradation

products

(PDF’s),

streptolysin O, and human immunodeficiency virus (HIV) antibodies. The assays are
rapid (minutes) and visual, and can be used either qualitatively or semi-qualitatively.
They are used widely in hospital laboratories in kit form.
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1.6 Reagents

1.6.1 Antibodies

1.6. LI Polyclonal antibody
Polyclonal antisera represents the total population of antibodies present in animal
serum, with each antibody representing the secretory product from a single lymphocyte
clone.

When

an immunogen containing many epitopes is injected

into

an

immunocompetent host, each epitope is recognised by a single lymphocyte clone via
specific antibody displayed on its surface. Each clone is thus stimulated to differentiate
and proliferate (often with the help of T-cells) into antibody-producing plasma cells.
Therefore, many different antibodies are produced in response to the immunogen (i.e.,
polyclonal), each one having specificity for a single epitope. Polyclonal antisera to a
specific immunogen is not only heterogeneous with respect to specificity, but is also
heterogeneous with respect to affinity. Therefore, the affinity is an average of the
combined affinities of the individual antibodies for their specific epitopes.
There is no formal reliable guidelines for polyclonal antibody production, but there are
a number of factors which must be taken into account, for example, the nature of the
antigen, immunological adjuvants, choice of animal, routes of immunisation, dosage of
immunogen, and immunisation schedule (Burrin and Newman, 1991; Dunbar and
Schwoebel, 1990; Abdul-Ahad and Gosling, 1994; Schimpl, 1993).
Not all antigens can induce a good immune response (haptens) and therefore need to
be coupled to larger molecules such as bovine serum albumin (BSA) to render them
immunogenic. The immunogen preparation must be of very high purity, since in a
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protein preparation that contains as little as 1% contamination, the majority of
antibodies may recognise that contaminant if it is highly immunogenic.
Adjuvants, substances which non-specifically enhance the immune response to an
immunogen, are also of importance in the production of polyclonal antisera. The most
frequently used adjuvants are the water-in-oil emulsions with the immunogen in the
aqueous phase (e g., Freund’s incomplete adjuvant), or one may use a microbial
antigen in the mixture to further enhance the adjuvant properties, e g., heat-killed

Mycobacterium tuberculosis in Freund’s complete adjuvant. Other adjuvants include
alum hydroxide (alum), saponins complexed to membrane protein antigens, bacterial
products such as lipopolysaccharide (LPS) and muranyl dipeptide (MDP), liposomes,
and latex particles.
The major species used for the production of polyclonal antisera are rabbits, sheep,
goat, guinea pig, and donkey, with the larger animals being more popular for
commercial-scale production. The age of the animal is important, since newborn
animals are unable to synthesise antibody and old animals show a reduced response
when compared to that seen in their prime. Some particular strains or breeds of animal
may offer advantages over others with respect to the response against a particular
immunogen, e g., guinea pigs for insulin antisera.
Routes of immunisation and doses used vary greatly, but generally primary doses
involve low concentrations of immunogen injected intradermally. Secondary treatments
may involve subcutaneous routes at two to four sites. A suitable primary dose for a
rabbit or guinea pig is about 100 pg (200-500 pg for sheep and goats), with 10-50% of
the primary dose used for booster doses. Low doses produce higher affinity antibody,
since at high concentrations of immunogen, B-cells with low affinity immunoglobulin
receptors may be recruited. After the primary injection, the antiserum titre rises
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gradually and reaches a plateau after 4-6 weeks, after which a slow decline occurs.
Following the booster injection, the titre reaches a maximum after 10-14 days, at which
time the antibody should be harvested. Subsequent boosters may or may not produce
improvements in titre.
Once the animal has been bled, partial purification of immunoglobulin from the
antiserum may be obtained using ammonium sulphate fractionation plus DEAE
(dimethylaminoethyl) ion-exchange chromatography, or using protein A/G affinity
chromatography. However, for the isolation of a pure population of antibodies, affinity
extraction with immobilised antigen or antibody is desirable.

Primary response
(Maximum litre @ 4-6 weeks)

Inject ~10()
highly pure immunogen'
(<1% contamination) intradermally (eb. multiple sites

Booster dose^ subcutaneously @ 24 sites (10-50% of primary dose)

Secondary response
(Maximum litre 1014 days post
injection)

To non-specifically enhance the immune response use 'Freund's complete adjuvant or ^Freund's incomplete adjuvant

t
Purification of antibody
(e g.. Affinity chromatography)

Bleed animal

Figure 1.6.1 Possible immunisation schedule for polyclonal antibody production.

1.6.1.2 Monoclonal antibody
Monoclonal antibodies are defined as antibodies derived from one lymphocyte clone,
and are thus homogeneous. They are not inherently different from antibodies making
up polyclonal antisera, since polyclonal antisera is only a mixture of monoclonal
antibodies. Monoclonal antibodies offer many advantages over polyclonal antibodies,
including an improved continuity of supply and better defined specificity. As a result.
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they are widely used in immunoassay (Brailly, 1994; Piran et al., 1995; Thompson et
al., 1984). However, they are not without their limitations (Table 1.6.1). The
increasing popularity of monoclonal antibodies amongst workers has been illustrated
by Gosling (1990). He has shown that the percentage of new immunoassays (published
in Clinical Chemistry) using monoclonal antibodies has risen from 0% in 1980 to >50%
in 1990. One would assume that the percentage is even higher today.

Table 1.6.1 Comparison of monoclonal and polyclonal antibodies

Advantages of monoclonal over polyclonal antibody
1. Indefinite supply of antibody with constant characteristics.
2. Obtained from impure immunogen. Require highly purified immunogen for
polyclonal antibody production.
3. Monoclonal antibody is more specific.
4. Affinity and fine specificity are better defined.

Advantages ofpolyclonal over monoclonal antibody
1. Higher affinities predominate.
2. Easier and cheaper to produce.
3 Form precipitin lattices with most antigens. However, monoclonal antibodies are
often used in mixtures to overcome this problem.
4. Monoclonal antibodies rely on detection of only a single epitope.
(Compiled using data from Siddle, 1985; Dunbar and Skinner, 1990)

The technique of monoclonal antibody production (Abdul-Ahad and Gosling, 1994;
Burrin and Newman, 1991; Dunbar and Skinner, 1990) relies on the fusion of normal
B-cells (plasma cells) with myeloma cells (cancerous cells of the B-cell lineage) to
produce hybridomas (Figure 1.6.2). The hybridoma has properties of both cells,
possessing the antibody producing ability of plasma cells and the immortality of
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myeloma cells. The majority of monoclonal antibodies are generated by means of mice
spleen (BALBc) and murine myeloma cells, but rat/rat, rat/mouse, sheep/mouse, and
human/human hybridomas have also been developed.
Immunisation of the mouse is usually with 10-100 |ig of immunogen in 250 fal of
emulsion with Freund’s complete adjuvant injected intradermally or subcutaneously,
followed by boosters of similar amount after 4-6 weeks using Freund’s incomplete
adjuvant. Basically, isolated spleen cells from the mouse are fused with myeloma cells
using polyethylene glycol (PEG). All cells are grown in hypoxanthine, aminopterin, and
thymidine medium (HAT), which is selective only for spleen-myeloma hybrids. Since
successful fusions are rare, only a few wells contain small clusters of viable cells,
however, not all produce antibody, and even if they do, many will not secrete antibody
specific for the antigen of interest. After subculture, wells are then screened for
antibody of interest, usually using solid-phase antibody capture assays, followed by
subculture of antibody positive clones to ensure purity. Production of antibody can be
carried out in homogeneous suspension in flat tissue culture flasks, or hybridomas can
be established in the peritoneal cavity of BALB/c mice (with 10% contamination from
non-specific antibody).
With the advent of monoclonal antibodies has come the production of anti-idiotype
antibodies, antibodies with specificity for the paratope of a specific immunoglobulin. If
a homogeneous (monoclonal) antibody is injected into an immunocompetent animal,
antibodies may be produced with specificity for the paratope (Dunbar and Skinner,
1990). These antibodies have been used in competitive assay format, as described
earlier (Thompson et al., 1985).
In addition, Bugari et al. (1990) have reported on the use of bispecific antibodies,
obtained through the fusion of two hybridomas producing antibodies to p27

galactosidase and human lutropin. The resultant antibody, used as tracer antibody in a
sandwich ELISA format, had more reactivity of both antibody and enzyme when
compared to traditional antibody-enzyme conjugates.

Immunogen

Myeloma Cells
(Lymphoma producedfrom cells
of the B-cell lineage)

Resulting suspension
distributed among a large
number of small subcultures.

Cells are grown in a selective medium,
m which unfused cells die but hybrid cells live.

Single cells are subcultured and screened to identify those cells making required antibody.
Cultures are not necessarily monoclonal - require one or more cloning steps.

Figure 1.6.2 Monoclonal antibody production.

1.6.1.2 Antibody fragments
Antibodies are essentially biflinctional molecules, containing specific sites for
interaction with antigen (located in the Fab region) and interaction with the other
components of the immune system (Fc region) (Figure 1.6.3). Antibodies also interact
with specific proteins such as proteins A and G, via the Fc region, a property which has
been exploited successfully in immobilising antibodies to solid supports (Lu et al..
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1996) and in the production of labelled antibody using a protein A-enzyme conjugate
(Kobatake et al., 1990).
However, despite these developments, the Fc portion of the IgG molecule is often
unnecessary and even undesirable in an antibody to be used as an immunoassay
reagent. The Fc in a labelled antibody may bind to either complement or rheumatoid
factor present in the sample, thus increasing the amount of label non-specifically bound
(Gosling, 1990). Moreover, the presence of Fc in an immobilised antibody may
correspondingly act as a binding site for the same proteins and result in blocking of the
analyte-specific binding sites (Gosling, 1990). Also, the Fc portion of the IgG molecule
is hydrophobic, causing high non-specific binding of IgG when used as label (Ishikawa
etal., 1989).
The Fc portion can be removed, without impairment of antigen binding, by digestion
with either papain or pepsin to yield monovalent Fab or divalent F(ab)’2, respectively
(Figure 1.6.3) (Ishikawa,

1987). Reduction of F(ab)’2 yields monovalent Fab’

(Ishikawa, 1987).

Pepsin cleavage point
Papain cleavage point

Figure 1.6.3 The various regions of IgG, produced hy papain and pepsin cleavage.
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Many workers have turned to univalent Fab’ fragments as labels to reduce non-specific
binding (Ishikawa et al., 1982, Ruan et al., 1987; Hashida and Ishikawa, 1990; Aubin
et al., 1997). In these cases, the Fab’ fragment is conjugated to enzyme by selective use
of thiol groups in the hinge of Fab’, distal to the antibody binding site. Fab’ fragments
labelled by the non-hinge method have higher non-specific binding and lower antigen
binding (reduced by 50-65%) than those prepared by the hinge method (Ishikawa et
al., 1989).
Fragments of antibodies have also been utilised in non-enzymatic immunoassays, in
which F(ab)’2 fragments are coupled to latex particles for use in particle-aided
immunoassays (Borque et al., 1993; Collet-Cassart et al., 1981; Borque et al., 1995).
In addition, Fab’-coated liposomes containing sulphorhodamine B have been used in a
sandwich-type format for urinary microalbumin (Frost et al., 1996b).

1.6.2 Labels
The principal factors determining the suitability of a labelling substance include specific
activity, ease of labelling, ease of endpoint determination, associated hazards, and
possibilities for convenient assay formulation or homogeneous operation (Gosling,
1990). The specific activity is of primary importance, since high specific activity is
essential for developing immunoassays with low detection limits.

1.6.2.1 Radioisotopes
Radioisotopes were introduced into immunoassay in 1960 (Yalow and Berson, 1960)
and very much represent the traditional label. Flowever, their use has declined
significantly over recent years due primarily to associated radiation hazards. Gosling
(1990) has shown that between 1980 and 1990 the use of radioisotopes as labels
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decreased from 50% to an apparently stable 25% of new assays. Despite this fact,
about 70% of commercial assays in 1994 still used isotopic labels (Gosling, 1994).
The criteria for the selection of a suitable radioactive tracer are half-life, specific
radioactivity (disintegration/second or Becquerels), and practicability of labelling
(Simonnet and Guilloteau, 1993). Since the half-life of

is only 8 days and the

specific radioactivity ofis 2.33 x 10'^ TBq/mmol (Table 1.6.2), neither is employed
as label in immunoassay (Simonnet and Guilloteau, 1993).

with a half-life of 60

days, is a good compromise and is therefore the most popular radioisotope used
(Simonnet and Guilloteau, 1993). However, because the iodine atom is relatively large,
it proved unsuitable for small molecules such as steroids, as it interfered with antibody
binding (Edward, 1992). Although

can be substituted directly for a hydrogen

present in the molecule to be labelled, making it suitable for low molecular weight
molecules, its relatively expensive liquid scintillation detection and low specific
radioactivity means that

is often used for labelling steroids despite the steric

hindrance (Edwards, 1992).

Table 1.6.2 Half-lives and specific radioactivity of radioisotopes

Radioisotope

Half-life in days

13,1

8

Specific radioactivity
(TBq mmol*)
600

32p

14.3

336

125|

60

80

''Co

271.4

18

^H

4475

1.07

14c

2.06 X 10^

2.33 X 10'^

*TBq = terabecquerel =10^^ becquerel
(From Simonnet and Guilloteau. 1993)
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The specific activity of a tracer is a direct consequence of the ratio of radioisotope to
carrier molecule in the tracer and the activity of the radioisotope. Theoretically, the
specific activity could be increased by using several molecules of isotope per molecule
of substance. However, since this often leads to a loss in immunoreactivity, the ratio
rarely exceeds 1:1 (Edwards, 1992; Simonnet and Guilloteau, 1993).

1.6.2.2 Enzymes
Over recent years, the decline in the popularity of radioisotopes has been associated
with an increase in the use of enzymes as labels (Gosling, 1990), since enzymes offer
many advantages over radioisotopes, including the lack of radiation hazards and longer
shelf-life (Table 1.6.3). In addition, a single enzyme molecule can act upon its substrate
(present in large excess) to generate many product molecules in a short time.
Conversion rates of 100-1,000 molecules per enzyme molecule per second gives a
large degree of signal amplification (Gudgin Dickson et al., 1995). Product molecules
are commonly detected by colorimetry, but if even greater sensitivity is required,
fluorogenic substrates may be used. Alternatively, one may use luminescent (bio- and
chemi-) assays, in which light is emitted through the direct action of enzyme on
substrate or indirectly through the channelling of the product into further reactions.
The ideal enzyme has a high turnover number, low Km, is stable upon storage (both in
free and conjugated form), is pure or easy to prepare, is easy to conjugate and easily
detectable, and is preferably absent from organisms from which samples are taken
(particularly for homogeneous assay) (Porstmann and Kiessig, 1992; Tijssen, 1993). In
addition, its chromagenic substrates should be water soluble, stable, odourless,
colourless, non-mutagenic, non-toxic, and form product with a high molar extinction
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coefficient and a broad absorbance maximum between 400 and 600 nm (Porstmann
and Kiessig, 1992). Unfortunately, no such enzyme exists.

Table 1.6.3 Comparison of enzyme with radiolabels in immunoassay
a) Advantages of enzyme labels
(i)

No radiation hazards occur during labelling or disposal of waste.

(ii) Enzyme-labelled products can have a long shelf-life, e g., 1 year or more.
(Hi) Equipment for enzyme assay can be inexpensive and is generally
available.
(iv) Homogeneous assays can be completed in a few minutes.
(v) Heterogeneous assays are ideal for visual qualitative tests.
(vi) Multiple simultaneous assays are possible.

b) Disadvantages of enzyme labels
(i)

Plasma constituents may affect enzyme activity.

(ii) Assay of enzyme activity can be more complex.
(Hi) Less control of enzyme labelling reactions.
(iv) At present homogeneous enzyme immunoassays have limited sensitivity.
(Modified from Blake and Gould, 1984)

A large number of enzymes are currently available, but in approximately 65% of all
assays horseradish peroxidase is used, whereas alkaline phosphatase is used in about
25% of assays (Tijssen, 1993). This is in partial agreement with Gosling’s (1990)
observation that, of all new enzyme immunoassays published in 1990, 50% used
horseradish peroxidase and 25% used alkaline phosphatase. Other enzymes used
include (3-galactosidase, urease, acid phosphatase, glucose oxidase, glucoamylase,
carbonic

anhydrase,

acetylcholinesterase,

xanthine

oxidase,

lysozyme,

malate

dehydrogenase, glucose-6-phosphate dehydrogenase, ribonuclease (Tijssen, 1993),
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metapyrocatechase (Kobatake et al., 1990), thrombin (Merenbloom and Oberhardt,
1995), and hexokinase (Litman et al., 1980).

1.6.2.2.1 Horseradish peroxidase
Horseradish peroxidase (HRP) is by far the most common label used in enzyme
immunoassay, its popularity at least partly stemming from its high turnover number,
the variety of sensitive assay systems available, its suitability for diverse conjugation
procedures, and its small molecular size (40,000 Da) (Gosling, 1990). Peroxidase
reacts with its substrate, H2O2, decomposing it to H2O by a hydrogen donor (DH2), the
resulting oxidised hydrogen donor representing the final product, measured by its
absorbance in the visible spectrum (Figure 1.6.4) (Tijssen, 1993; Johannsson, 1991).
Reactions are carried out at neutral or slightly acidic pH (Johannsson, 1991),

H2O2 + 2DH2

HRP

-►

2H2O

+ D2H2

Figure 1.6.4

Several chromagenic substrates have been used in the assay of horseradish peroxidase,
including o-phenylenediamine (oPD), 3,3’,5,5’-tetramethylbenzidine (TMB), and 2,2’azino-di-(3-ethylbenzothiazoline-6-sulphonate)

(ABTS)

(Johannsson,

1991).

The

specific activity with ABTS is about 1,000 U/mg at 25°C, and that of other substrates
is a few fold higher (Johannsson, 1991). To increase the sensitivity of horseradish
peroxidase detection, the fluorogenic substrates, p-hydroxyphenylacetic acid (HPAA)
and 3-()9-hydroxyphenyl) propionic acid (HPPA), may be used (Porstmann and Kiessig,
1992). In addition, horseradish peroxidase detection may be enhanced via the
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luminescent oxidation of cyclic diacylhydrazides such as luminol (Figure 1.6.5)
(Kricka, 1991, Truchaud and Garcera, 1993).

Luminol + H O
2

HRP

2

■> Light

Figure 1.6.5

However, high background signals, low light intensity, and a rapid decay of light
emission limit the reaction (Kricka, 1991; Truchaud and Garcera, 1993). With the
addition of small amounts of phenols, naphthols, and amines as “enhancers”, the light
intensity of the emission is increased by several orders of magnitude (2,500 fold after
30 seconds), there is a reduction in the background emission from the luminol-peroxide
blank, and the light emission is a long-lived glow (>30 min) (Kricka, 1991; Truchaud
and Garcera, 1993). li et al. (1993) used a chemiluminescence detection system that
included the luminol derivative, L-012, and 4-(4-hydroxyphenyl)thiazole as an
enhancer. The detection limit of the assay for human basic fibroblast growth factor
(hbFGF) was ten times more sensitive than a previous immunoassay employing oPD as
substrate.
The practical detection limit of horseradish peroxidase using chromagenic substrates is
in the region of lO'^"* to 10'*^ mol, which is comparable to the commonly employed
radioisotope

(Johannsson, 1991). This appears to be in partial agreement with

Ishikawa (1987), who suggests that 25 and 50 amol of peroxidase can be detected in
10 min using oPD and TMB, respectively. With longer incubation (100 min), 5 amol of
horseradish peroxidase can be detected using TMB (Ishikawa, 1987). Using a
fluorogenic substrate (HPPA) in a 100-min incubation, the sensitivity may be increased
by 10-50 fold (Ishikawa, 1987).
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1.6.2.2.2 Alkaline phosphatase
Alkaline phosphatase (AP) is a dimeric glycoprotein of approximately 140 K molecular
mass and has a large number of free amino groups, which can be used for conjugation
without loss of enzyme activity (Johannsson, 1991). It hydrolyses numerous phosphate
esters of primary alcohols, phenols, and amines, with an optimum activity in the pH
range 9.5-10.5 (Johannsson, 1991). Using 1 mmol/1 diethanolamine buffer, pH 9.8,
containing 0.5 mmol/1 MgCb and 15 mmol/1 /7-nitrophenyl phosphate (pNPP), the
specific activity is 2,000 U/mg at 37°C (Johannsson, 1991, Tijssen, 1993). At 25"C,
activity is reduced to about half, but /?NPP suffers from spontaneous hydrolysis at
temperatures greater than 30°C (Tijssen, 1993). As alkaline phosphatase is larger than
peroxidase and the millimolar extinction coefficient of the nitrophenol product (18.3) is
lower than that of TMB product, the detectability of alkaline phosphatase with /?NPP is
not as good as that of peroxidase (Johannsson, 1991). According to Ishikawa (1987),
the detection limit of alkaline phosphatase using pNPP in a 10-min incubation is 10,000
amol, while Johannsson (1991) reports that as little as 30 amol of alkaline phosphatase
can be detected after 30 min with 150 pi ofpN?? substrate.
To increase the detectability of alkaline phosphatase using colorimetry, authors have
turned to amplification systems involving nicotinamide dinucleotide phosphate (NADP)
as substrate (Self, 1985; Moss et al., 1985; Stanley et al., 1985; Johannsson et al.,
1986; Dhahir et al., 1992). Alkaline phosphatase dephosphorylates NADP to NAD, the
catalytic activator for a NAD/NADH redox cycle (Figure 1.6.6). NAD is reduced to
NADH by the action of alcohol dehydrogenase. NADH is then subsequently oxidised
by the action of diaphorase, which simultaneously reduces /?-iodonitrotetrazolium
violet (TNT) to formazan. Reformed NAD is free to enter the cycle repeatedly.
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resulting in the production of several formazan molecules per molecule of NAD.
Stanley et al. (1985) used this amplification system in an assay for human thyroid
stimulating hormone (hTSH), obtaining a 70-fold increase in sensitivity over the
conventional assay using pNPP as substrate. Moss et al. (1985), in an assay for
prostatic acid phosphatase, reported an increase in sensitivity of the order of 175 times
that of conventional methods, while Dhahir et al. (1992) achieved a 10-fold
improvement on the sensitivity of proinsulin determination over previous assays.
Johannsson et al. (1986) claim that the system can detect 0.01 amol of alkaline
phosphatase after a 3-h incubation.

Ethanol

Acetaldehyde
1. Alkaline phosphatase

NADP

2. Alcohol dehydrogenase

NAD

NADH

Formazan

INT

Purple colour

Colourless

3. Diaphorase

Figure 1.6.6 Amplification of alkaline phosphatase label. NAD, produced by the
catalytic action of alkaline phosphatase on NADP, is reduced to NADH through the
action of alcohol dehydrogenase. NADH is subsequently oxidised by the action of
diaphorase, which simultaneously reduces a tetrazolium salt to a coloured product.

In addition, alkaline phosphatase may be detected through the use of bioluminescent
and chemiluminescent assays (Kricka, 1991), or using the flourogenic substrate, 4methylumbelliferyl phosphate (Ishikawa, 1987). The latter increases the sensitivity of
alkaline phosphatase detection by up to 1,000 fold (10 amol v 10,000 amol) when
compared to pNPP using the same incubation times (Ishikawa, 1987). In the
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bioluminescent assay, alkaline phosphatase cleaves the phosphate group from firefly Dluciferin-O-phosphate

to

liberate

D-luciferin,

which

is

a

substrate

for the

bioluminescent firefly luciferase reaction (Figure 1.6.7) (Kricka, 1991).

Firefly luciferin-O-phosphate-

AP

-► Firefly luciferin

Firefly luciferase

Firefly luciferin

■> Light

(1)
(2)

^77^ + O.
Figure 1.6.7 Detection of alkaline phosphatase label using bioluminescence.

The most sensitive and widely investigated chemiluminescent detection system for
alkaline phosphatase involves an adamantyl 1,2-dioxetane aryl phosphate, which is
dephosphorylated to a phenoxide intermediate that decomposes further to form
adamantanone and an aryl ester (the emitter) (Kricka, 1991). The light emission is in
the form of a glow and lasts for >1 h, and can be enhanced through the use of a variety
of substances (Kricka, 1991). Kricka (1991) suggests that as little as 0.01 and 0.001
amol of alkaline phosphatase can be detected using firefly D-luciferin-(9-phosphate
bioluminescence

and

adamantyl

1,2-dioxetane

enhanced

chemiluminescence,

respectively.
The sensitivity of alkaline phosphatase detection has also been enhanced using
amperometric detection of reaction products. Ciana et al. (1996), in an assay for afetoprotein in human serum, used p-hydroxyphenyl phosphate as substrate. The
hydrolysis product, hydroquinone, was detected by oxidative amperometry after a 10min incubation, giving a detection limit for alkaline phosphatase of 60 zmol (60 x 10'^’
mol) or 36,000 molecules. The detection limit for a-fetoprotein using amperometry,
0.07 ng/ml, was fourteen times lower than by photometry. Bauer et al. (1996) used a
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phenol-indicating biosensor, consisting of a Clark-type electrode covered by a
membrane with co-entrapped tyrosinase and quinoprotein glucose dehydrogenase.
Alkaline phosphatase cleaves phenyl phosphate to phenol, which is oxidised at the
sensor membrane by the oxygen-consuming tyrosinase via catechol to o-quinone
(Figure 1.6.8). The quinone is then reconverted to catechol by glucose dehydrogenase,
resulting in a 350-fold amplified sensor response to phenol. The oxygen consumption
of the enzyme couple in the presence of phenol is monitored as a decrease in current.
Using this recycling system, 320 zmol of alkaline phosphatase can be detected after a
57.5-min incubation with phenyl phosphate.

Figure 1.6.8 Schematic representation of the principle of alkaline phosphatase
measurement using amperometry. PQQ pyrroloquinolinequinone.

1.6.2.2.3 p-galactosidase
P-galactosidase (P-GAL) from E.coli is a tetramer of 465 K molecular mass (Tijssen,
1993). The most commonly employed substrate is oNPG and is hydrolysed at a rate of
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about 500 U/mg at 25“C using 50 mmol/1 phosphate buffer, pH 6.8, containing 1
mmol/1 MgCb and 2.6 mmol/1 substrate (Tijssen, 1993).
Johannsson (1991) suggests that (3-galactosidase does not appear to offer advantages
over alkaline phosphatase, however, Ishikawa (1987) reports that 1,000 amol of Pgalactosidase can be detected after a 10-min incubation using oNPG as substrate, as
compared to 10,000 amol of alkaline phosphatase under comparable conditions. Best
sensitivity is obtained using a bioluminescent assay involving oNPG as substrate
(0.0002 amol), but this requires numerous reagents and lengthy incubation steps
(Figure 1.6.9) (Kricka, 1991).

o-Nitrophenyl-p-D-galactoside—
P-D-Galactose + NAD
NADH + FMN+H^ —
FMNH2+O2

^-GAL

► P-D-Galactose + o-Nitrophenol

Galactose dehydrogenase

^ Galactonatc + NADH

NADH dehydrogenase--------------^
Luciferase ^ Long-chain aldehyde

^

■> Light + FMN

(1)
(2)

(3)
(4)

Figure 1.6.9 Detection of f}-galactosidase label using hioluminescence.

Alternatively, P-galactosidase label can be detected using an adamantyl 1,2-dioxetane
phenyl galactoside in an analogous manner to adamantyl 1,2-dioxetane aryl phosphate
used for alkaline phosphatase detection (Kricka, 1991). Using the fluorogenic
substrate, 4-methylumbelliferyl-p-D-galactopyranoside, as little as 0.2 and 0.002 amol
of P-galactosidase can be detected after 10-min and
respectively (Ishikawa, 1987).
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1,000-min incubations,

1.6.2.2.4 Amplification of signal
Modest signal amplification can be achieved through the direct coupling of a number of
enzyme molecules to the antibody or antigen (Johannsson, 1991). Alternatively, one
can use indirect labelling, in which the label determined at the end of the assay is not
the primary label (Avrameas, 1992). For example, in a two-site sandwich assay a
biotinylated secondary antibody may be detected using avidin as bridge between the
antibody and labelled biotin, or using labelled avidin (Avrameas, 1992). Since each
antibody may carry several biotin molecules and since avidin can bind biotin at ratio of
1:4, there is a large degree of signal amplification, resulting in between a 2 to 100-fold
increase in sensitivity over conventional procedures (Avrameas, 1992). As described
earlier, recycling systems may be used to enhance the detectability of enzyme label, the
most common being the NAD/NADH cycling system for the measurement of alkaline
phosphatase.
There are several naturally occurring examples of biological amplifiers, the well-known
cascade mechanism of blood clotting being a prime example. Coagulation cascades
olfer enormous amplification potential, because each enzyme molecule, in turn,
activates multitudes of other enzymes, leading to the formation of a fibrin clot
(Merenbloom and Oberhardt, 1995). Merenbloom and Oberhardt (1995) exploited this
natural amplification system in a homogeneous immunoassay of whole-blood samples
using thrombin as the label. However, this serine protease is the last cascade step,
representing the lowest level of amplification, but according to Merenbloom and
Oberhardt (1995), the technology is potentially applicable to immunoassays using
multiple cascade levels. With biotin as model analyte, a competitive homogeneous
immunoassay was developed using a biotin-thrombin conjugate in competition with
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biotin in control plasma for a limited number of sites on a monoclonal antibody. For
each test, a sample, inhibited biotin-thrombin conjugate, anti-biotin monoclonal
antibody, and paramagnetic iron oxide particles were mixed together and introduced to
a test-card reaction chamber. Because the conjugate is inhibited by p-amidinophenyl
ester of cinnamate, no clotting takes place during the initial immunoreaction. After a
brief incubation period, the card is illuminated with ultraviolet light, reversing thrombin
inhibition. However, only thrombin not bound by antibody can convert fibrinogen to a
fibrin clot. The clotting time is established photometrically through the change in
motion of the paramagnetic particles, which become trapped in the forming clot.
Because a high concentration of analyte results in a greater amount of free biotinthrombin conjugate and a faster clotting time than a low concentration, the clotting
time is inversely proportional to the concentration of analyte in the sample. The
detection limit of the assay was 200 to 1,000 nmol/1, with potential to decrease to 26
pmol/1 using factor Xa as label.

1.6.2.3 Enzyme-related labels
As discussed earlier, in addition to the use of enzymes as labels, prosthetic groups
(Morris et al., 1981), substrates (Burd et al., 1977; Wong et al., 1979), and inhibitors
(Bacquet and Twumasi, 1984; Finley et al., 1980) have been used as labels in
immunoassay.
In 1976, Carrico et al. described a cycling system for the sensitive detection of
nicotinamide 6-(2-aminoethylamino) purine dinucleotide (AENAD) used as label
(Figure 1.6.10). AENAD, serving as cofactor for lactate dehydrogenase, is reduced to
AENADH, with the simultaneous conversion of lactate to pyruvate. Through the
action of diaphorase, thiazolyl blue is reduced, the label serving as reducing agent.
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Resultantly, the label is restored to its original state, thus allowing it to participate in
further reactions.

Lactate

Pyruvate

1. Lactate dehydrogenase
2. Diaphorase

Ligand-AENAD

Ligand-AENADH

Thiazolyl blue

Thiazolyl blue

Reduced (measured @570 nm)

Oxidised

Figure 1.6.10 Amplification system for the detection of AENAD cofactor used as
label. The progress of the reaction is monitored spectrophotometrically at 570 nm.

Similarly, Schroeder et al. (1976) developed a system for the detection of ligandAENAD conjugates involving a bioluminescent reaction. Ligand-AENAD is reduced
through the action of alcohol dehydrogenase using ethanol as reducing agent (Figure
1.6.11, Reaction 1). AENADH is then channelled into reactions involving the use of
the NAD(P)/FMN-dependent luciferase from Photohacterium fisheri (Figure 1.6.11,
Reactions 2 and 3).

Alcohol dehydrogenase
Ligand-AENAD + Ethanol -------- ► Ligand-AENADH + Acetaldehyde (1)
NADH + FMN +

FMNH2+O2

dehydrogenas^^
Luciferase

^ FMNH.

■> Light + FMN

(2)

(3)

Long-chain aldehyde
Figure 1.6.11 Use of the bacterial luciferase reaction to detect cofactor conjugates.
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Carrico et al. (1976) and Schroeder et al. (1976) report that the ligand-AENAD
conjugates are not available for participation in their respective reactions when bound
by antibody, thus making them ideal for use in competitive homogeneous formats.

1.6.2.4 Luminescence
1.6.2.4.1 Fluorescence
Luminescence is the most general term for light emission from a chemical species,
fluorescence representing a specific type of luminescence, namely light absorption
followed by rapid light emission. In fluorescence, a single photon of light is absorbed
by a molecule (excitation) and re-emitted at a slightly longer wavelength (Stoke’s shift)
(Gudgin Dickson et al., 1995). Usually, the energy is emitted over a broad band in the
ultraviolet to visible range of the electromagnetic spectrum (Gudgin Dickson et al.,
1995) Theoretically, this should be the most sensitive detection method, since a single
label can be measured many times during a relatively short measurement interval
(Gudgin Dickson et al., 1995). In comparison, the signal provided by ’^^I represents
only one detectable event per second per 7.5 x 10^ molecules, so that only 0.000013%
of the label is detected every second (Wood, 1991). In addition, fluorescent assays do
not require expensive and unstable reagents, complex instrumentation or licensing, and
containment or disposal procedures, associated with the use of radioisotopes (Quinn,
1993).
A wide range of fluorescent molecules have been employed as labels in immunoassay,
the most widely used being the isothiocyanate derivatives of fluorescein and rhodamine
(Quinn, 1993). Fluorescein is regarded as one of the most useful low molecular weight
fluorophores available because if its high quantum yield in aqueous solutions (Quinn,
1993). Fluorescein and rhodamine have Stoke’s shifts of only 28 and 35 nm,
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respectively, and a time scale of emission in the order of 10'*^ to 10'^ seconds (Wood,
1991; Gudgin Dickson et al., 1995). As a consequence, a major limitation of these
labels is that background fluorescence tends to be severe due to light scattering and
background fluorescence from sample over a wide wavelength range of approximately
300-600 nm (Wood, 1991; Gudgin Dickson et al., 1995). In addition, the presence of
two fluorophores in close proximity can cause self-quenching if there is overlap
between emission and excitation energies (Wood, 1991; Gudgin Dickson et al., 1995).
These limitations can be overcome through the use of lanthanide chelates, consisting of
an organic molecule bound to a metal ion, e.g., europium (Eu^^), samarium (Sm'^),
terbium (Tb'^), and ruthenium (Ru"^^) (Gudgin Dickson et al., 1995). These labels have
several advantages over organic labels (Table

1.6.4), including a long-lived

fluorescence (microseconds to milliseconds), which allows selective detection by
delaying measurement until a set time after the excitation pulse, when all short-lived
species have decayed (Wood, 1991, Gudgin Dickson et al., 1995). In addition,
favourable emission characteristics such as a large Stoke’s shift (>200 nm for Eu '^)
and narrow emission band permits additional discrimination against other luminescent
species and scattered excitation light, through the use of wavelength filtering (Quinn,
1993; Gudgin Dickson et al., 1995).
The first time-resolved immunoassay system to be developed commercially was the
DELFIA system (dissociation-enhanced ligand fluorescence immunoassay), in which
antibody or antigen is labelled with a stable europium chelate (Wood, 1991). The
europium ion has weak fluorescence in this form, but on completion of the
immunoassay, the europium is released from the hydrophilic chelator into a highly
lipophilic environment, which enhances the fluorescence (Wood, 1991). Reagents used
include fluorinated aromatic P-diketones to promote absorption and energy transfer to
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the lanthanide ion, and synergistic reagents to increase the luminescence yield (Gudgin
Dickson et al, 1995).

Table 1.6.4
Advantages and disadvantages of organic and lanthanide chelate fluorescent labels

Fluorescent species

Advantages

Disadvantages

Typical organic

Chemically stable, high

Small Stoke’s shift and

labels such as

fluorescence yield.

short fluorescence

fluorescein

Can be used with conventional

lifetime; results in

fluorescence instrumentation.

interference from
background signals.
Fluorescence yield
temperature and
environment sensitive.

Lanthanide chelates

Large Stoke’s shift, narrow band

Metal-complex stability

emission and long luminescence

may be low; requires

lifetime.

special handling to ensure

These properties permit selective

chelate binding.

discrimination against usual

Relatively low

background signals by

fluorescence yield

wavelength and temporal

compared with the best

filtering.

organic fluorophores.

Luminescence relatively

Specifically tailored time-

insensitive to environment.

gated instrumentation

temperature.

required for selective
detection.

(From Gudgin Dickson et al., 1995)

Interestingly, Madersbacher et al. (1993) compared chelates of europium with
horseradish peroxidase and

as detector labels used in solid-phase two-site

immunometric determination of follicle-stimulating hormone (FSH). Using the same
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monoclonal antibodies in all assays, IFMA achieved the best detection limit (2 ng/1 v’s
100 ng/1 with IRMA and 8 ng/1 with lEMA), the widest measuring range (2-160,000
ng/1), and the greatest signal-to-noise ratio (13,000:1 at 160,000 ng/1). The authors
accredit this superiority to the characteristics of the europium-conjugated monoclonal
antibodies and to the fluorescence detection system, i.e., the dissociative enhancement
principle for europium in combination with a fluorometer for time-resolved detection.
With standard labelling procedures, about 10-15 molecules of europium chelate, but
only 2-3 atoms of

and only 2-3 molecules of horseradish peroxidase, can be

covalently linked to monoclonal antibody (Madersbacher et al., 1993).

1.6.2.4.2 Chemiluminescence and bioluminescence
Chemiluminescence is light emission that arises during the course of a chemical
reaction, whereas bioluminescence is a special type of chemiluminescence found in
nature, in which light emission is facilitated by a catalytic protein (Kricka, 1991). These
detection systems are attractive, since they are sensitive, fast (signal generated in a few
seconds), simple, and use non-hazardous reagents (Kricka, 1991). The sensitivity
largely stems from the fact that no external light source is required, as would be the
case for fluorescence or colorimetric measurements, meaning that all light reaching the
detector is as a result of the reaction (Kricka et al., 1991). The majority of labels used
in luminescence immunoassays are chemiluminescent in nature (usually derivatives of
luminol, isoluminol, and acridine), since they are stable, and relatively cheap and easy
to couple to proteins without loss of activity (Wood, 1993). The efficiency of the
chemiluminescent reactions (number of photons emitted/number of molecules reacting)
is generally very low (<5%), however, specially synthesised oxamides have an
efficiency of greater than 30% (Wood, 1984). In any event, the detection limits are still
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equal to or better than that of radioisotopic labels

with acridinium esters

achieving a detection limit of 0.8 amol (Wood, 1984; Kricka et al., 1991). Added
disadvantages include signal quench effects by serum/plasma components when labels
are used in liquid-phase immunoassays, an inability to repeat measurements once the
chemical reaction has taken place, and short-lived luminescence (e g., ~25 seconds for
luminol and isoluminol) (Wood, 1984; Kricka et al., 1991).
Generally,

chemiluminescent reactions proceed without biological

intervention,

however, peroxidase has been used successfully to provide “active oxygen” to oxidise
luminol label (Wood, 1993). The light is produced continuously in the form of glow as
the peroxidase generates nascent oxygen from H2O2 (Wood, 1993). As discussed
previously, chemiluminescent reactions may be used to detect enzyme labels, e g.,
horseradish peroxidase, alkaline phosphatase, and P-galactosidase.
Bioluminescence is light emission associated with biological systems. The components
involved include a luciferin in reduced form as substrate, together with a luciferase
(label) as specific enzyme (Wood, 1993). There are two main bioluminescent systems,
one of which is ATP-dependent (Figure 1.6.7, Reaction 2) and the other of which is
NAD(P)/FMN-dependent (Figure 1.6.11, Reactions 2 & 3) (Wood, 1991, Wood,
1993). The former is derived from the American firefly, the most commonly used
luciferin-luciferase system, and the latter is present in marine bacteria such as Vibrio
species (Wood, 1991; Wood, 1993). Using the firefly system, the detection efficiency
is much higher than for radioisotopes, since light efficiency can approach 100%
(Kricka et al., 1991). Limitations of these systems include expense of reagents,
unstability of enzymes, and complications in preparation of labels (Wood, 1984).
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1.6.2.5 Alternative labels
Synthetic lipid bilayer vesicles (liposomes) containing carboxyfluorescein (CF) have
been used as label in a homogeneous sandwich-type immunoassay to determine ferritin
in human serum (Ishimori and Rokugawa,

1993). The liposomes, containing

immobilised monoclonal anti-ferritin antibody and encapsulated CF, were incubated in
sample containing ferritin. After incubation, a second antibody and complement were
added, resulting in the formation of a sandwich of antibody, ferritin, and complement
on the liposome surface. The fluorescence from the liposomes lysed by the action of
complement was monitored, whilst CF trapped in liposomes was not fluorescent
because of self-quenching. Using this system, ferritin in the range of 10-1,000 pg/1
could be determined in human sera. Similarly, liposomes entrapping the dye
sulforhodamine B were used to develop an assay for anti-cardiolipin antibodies (Frost
et al., 1996a) and urinary microalbumin (Frost et al., 1996b). The use of liposomes as
primary labelling substances leads to amplification, because the lysis of each vesicle
releases many molecules of the trapped indicator (Gosling, 1990).
DNA has also been used successfully as label in a solid-phase two-site sandwich
immunoassay for the measurement of hTSFI and hCG (Joerger et al., 1995). The DNA
label is detected using specific primers in the polymerase chain reaction (PCR),
producing amplification products with length and sequence identical to those of the
original label. Amplification products are then analysed by agarose gel electrophoresis.
Detection limits for hTSH (10'*^ mol) and hCG (5 x 10‘** mol) exceeded those of
conventional enzyme immunoassays by two to three orders of magnitude (Joerger et
al., 1995). These principles have been extended to the simultaneous detection of
hTSH, hCG, and |3-galactosidase in a solid-phase two-site sandwich immunoassay
format, using three specific monoclonal antibodies as capture and three specific
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oligonucleotide-labelled monoclonals (Hendrickson et al., 1995). The labels, which are
of differing lengths, possess the same primer binding sequences, thus permitting the use
of the one primer for the detection of all three labels. Once the PCR is complete,
amplification products are analysed using agarose gel electrophoresis. Since the
oligonucleotide labels are of differing lengths, the amplification products differ in
length and mobility on the agarose gel. The latter characteristic allows perfect
discrimination between labels. Similarly, authors have used enzyme-coding DNA
fragments as labels (Christopoulis and Chiu, 1995). The DNA label is detected with
high sensitivity by measuring the enzyme activity of firefly luciferase after expression.
Sensitivity is derived mainly from the combined transcription/translation process, since
transcription produces several mRNA molecules per DNA template, and translation, in
turn, produces more than one protein molecule from each transcript. Therefore, for
each DNA label there is a large yield of protein. In addition, since the DNA label
encodes an enzyme, the amplification is further enhanced due to substrate turnover
Using this system, the authors detected as little as 3,000 molecules of DNA label and
50,000 molecules of antigen.
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1.7 Separation Methods

Several methods can be used to separate bound from free label in heterogeneous
immunoassay. In competitive immunoassays, liquid-phase separation can be achieved
using either polyethylene glycol (PEG) (Bailey, 1994; Osterman et al., 1979), second
antibody (Al-Bassam et al., 1978; Blake et al., 1982; Bailey, 1994), or both (Carstens
et al., 1997). Using low concentrations of PEG, one can bring about the precipitation
of antibody molecules, whilst leaving antigen in solution (Bailey, 1994). Once the
precipitate is formed, the contents are centrifuged, the supernatant poured off, and the
signal associated with either is measured (Bailey, 1994; Osterman et al., 1979). The
alternative method relies on the use of antiserum directed against the first antibody, for
example, Al-Bassam et al. (1978) used donkey anti-sheep antibody to precipitate a
sheep antibody employed in a competitive assay for nortriptyline. In addition, charcoal
has also been used to absorb free label, with separation again being achieved using
centrifugation (Gosling, 1990).
However, by far the most convenient and efficient methods involve the use of solid
phases, with solid-phase methods representing 70% of all new immunoassays in 1990
(Gosling, 1990). Kaibe et al. (1990) used antibody complexed to bacterial cell walls in
a competitive immunoassay format for the epileptic drug, Zonisamide. Once the
immunocompetition had taken place, the insolubilised antibody was removed via
centrifugation and the signal associated with precipitate was measured. Similarly, Ko et
al. (1992) used a second antibody coupled to iron to precipitate the first antibody.
However, since these types of assay require the use of a centrifuge, their usage has
declined over the years to <10% of new solid-phase assays in 1990 (Gosling, 1990).
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More commonly, antigens and antibodies are immobilised to solid phases which allow
separation to be achieved via several washing steps. Table 1.7.1 highlights some of
these solid matrices employed in heterogeneous immunoassay. By far the most popular
solid-phase system employed is the 96-well plastic microtitre plate, representing 70%
of all new solid-phase assays in 1990 (Gosling, 1990). While a range of plastics may be
used, polystyrene appears to be the most popular. The popularity of microtitre plates
largely stems from the large batches of samples that can be assayed on one plate
conveniently and quickly using purposefully

designed

multi-channel

pipettes,

automated plate washers, and readers.

Table 1.7.1 Examples of some solid matrices used in heterogeneous immunoassay

Particulate
Polystyrene balls

(l.shikawa et al., 1990; Ha.shida and I.shikawa, 1990; l.shikawa et al., 1982)

Glass balls

(Ruan et al.. 1987)

Controlled-pore glass beads

(Sportsman et al., 1983; Ogbonna et al., 1995)

Magnetic beads

(Ogbonna et al., 1995; Pollema and Ruzicka, 1994)

Sepharose

(Nilsson et al., 1993)

Sephadex

(Freytag et al., 1984)

Poros beads

(Kronkvi.st et al., 1997)

Solid surface
Cellulose membranes

(Newman and Price, 1991)

Plastic tubes

(Thijssen et al., 1991; Burgi et al., 1988)

Plastic microtitre plates

(Brailly et al., 1994; li et al., 1993; Aubin et al., 1997; Luppa et al., 1995)

In recent years, separation has been achieved with a high degree of reproducibility
using capillary electrophoresis (CE) (Schmalzing et al., 1995, Novotny, 1996).
Schmalzing et al. (1995), in a competitive immunoassay for cortisol, used CE to
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separate free cortisol-fluorescein conjugate from cortisol-fluorescein conjugate bound
to specific antibody. The signal associated with either could then be measured in the
capillary using laser-induced fluorescence. Alternatively, direct CE may be used in onesite immunoassay to separate labelled antibody-antigen complexes from an excess of
unreacted labelled antibody (Schmalzing et al., 1995). However, the molecule being
measured needs to be large enough to effect a change in the mobility of the antibody
when bound and is therefore of little use for small molecules such as cortisol
(Schmalzing et al., 1995).
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1.8 Immobilisation of Biomolecules on Surfaces

Biomolecules (antibodies and antigens) may be attached to surfaces using either
passive

adsorption,

consisting

of

primarily

hydrophobic

interactions

or

hydrophobic/ionic interactions between the biomolecules and the surface (Gibbs,
1995a), or covalent attachment (Gibbs, 1995a; Butler, 1992; Cabral and Kennedy,
1991). Using the latter method, molecules may be attached to surfaces via amino, thiol,
carboxyl, phenolic, guanido, imidazole, disulphide, indole, thioether, and hydroxyl
functional groups (Cabral and Kennedy, 1991). Support materials generally do not
possess reactive groups, but rather hydroxyl, amino, amide, and carboxyl groups,
which have to be activated using functional cross-linking reagents in order to
immobilise the biomolecules (Cabral and Kennedy, 1991). For example, amino surfaces
can be activated through gluteraldehyde pre-treatment and a carboxyl surface may be
activated using a carbodiimide (Douglas and Monteith,

1994). However, for

polystyrene, carboxyl and amine groups have to grafted to the surface before using the
functional cross-linker (Gibbs, 1995a). In addition, functional and covalently reactive
groups such as N-oxysuccinimide (to couple amine groups), maleimide (to couple free
sulphydiyl groups), and hydrazide (to couple periodate-activated carbohydrate
moieties) can be grafted onto a polystyrene surface (Gibbs, 1995a).
For the activation of polysaccharides such as Sepharose, numerous methods may be
used to activate the surface, one of which involves the use of cyanogen bromide
(CNBr). The popularity of CNBr-activated Sepharose is due to its high capacity for
immobilised reactants, for example, 25-60 mg of protein can be immobilised on 1 ml of
gel

(CNBr-activated

Sepharose 4B

Instructions,

Pharmacia-Biotech,

Uppsala,

Sweden). At high pH, CNBr introduces very reactive cyanate esters (-0-C=N) and less
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reactive imidocarbonates (>C=NH) into the matrix by reacting with endogenous
hydroxyl groups (Cabral and Kennedy, 1991). Therefore, the reactive matrix is then
suitable for the coupling of amine-containing ligands (Cabral and Kennedy, 1991).
Sepharose is now supplied commercially in the reactive form, thus eliminating the need
to use CNBr, which is extremely toxic. Nilsson et al. (1993) used tresyl chloride
activation for Sepharose CL-4B, a process which converts the hydroxyl groups of the
matrix into active sulphonates, thus making it suitable for coupling amine-containing
ligands (Cabral and Kennedy, 1991).
While covalent coupling may be obligatory for the coating of most solid phases,
polystyrene and other plastics may be coated using passive adsorption (Gibbs, 1995a).
The interactions that take place are greatly affected by the concentration of
biomolecule being adsorbed, the nature of the buffer used (ionic strength and pH), and
the time and temperature of incubation (Gibbs, 1995b). In addition, the binding of
molecules is prevented by non-ionic detergents (Gardas and Lewartowka, 1988).
For immobilisation to plastics, authors generally use a 0.05 mol/l carbonate buffer, pH
9.6, with incubations carried out overnight at 4”C (Munro and Stabenfeldt, 1984; Ko et
al., 1992; Chlang et al., 1992; Papoian et al., 1991), however, the conditions used may
vary between workers. For example, coating has also been achieved using carbonate
buffers incubated for 4 h at 4“C (li et al., 1993) and for 6 h at 25°C (Thompson et al.,
1985), or using phosphate buffers (pH 7 2-7.4) incubated overnight at room
temperature (Aubin et al., 1997), for 3 h at 37°C (Rappuoli et al., 1981), and for 2 h at
room temperature (Noe et al., 1992). In contrast, KrachmalnicofiP et al. (1990) used a
Tris buffer, pH 9.0, incubated at 4°C overnight. Generally, incubation times may be
shortened using increased temperatures (Gibbs, 1995b), however, studies using
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polystyrene have shown that 90% of maximum binding occurs within 2 to 6 h, even at
4“C (Pesce et al., 1977).
The optimum concentration for coating plastic microtitre plates and tubes typically lies
between 0.4-10 p-g/ml (Krachmalnicoff et al., 1990, Papoian et al., 1992; Noe et al.,
1992; Aubin et al., 1997; Dhahir et al., 1992; Munro and Stabenfeldt, 1984). Higher
concentrations may lead to an inefficient immunoassay, for example, Kobatake et al.
(1990) noticed a reduced signal in a two-site sandwich assay when using a primary
antibody concentration of 1 mg/ml. This is because at high concentrations the
molecules may bind each other loosely, forming multiple layers, which are unstable and
can peel off during the assay (Kemeny, 1992). To coat polystyrene and glass balls with
IgG, higher concentrations (100 |ug/ml) have been used (Ishikawa et al., 1980;
Ishikawa et al., 1982; Ruan et al., 1987), since several balls provide a larger surface
area for binding.
When using passive adsorption, the binding capacity of polystyrene is approximately
100-200 ng IgG/cm^ (Gibbs, 1995a), which is equivalent to 4 x 10^ to 8 x 10^
molecules/cm^. Conradie et al. (1983) reported that partial denaturation of antibody
using low pH (2.5), 3 mol/l urea, and temperatures as high as 82°C enhanced the
ELISA reaction colour in two-site sandwich assays for ferritin and hepatitis B surface
antigen. They attributed this to an increased exposure of new hydrophobic domains,
leading to binding to regions on the polystyrene surface normally not coated by nonperturbed molecules. Moreover, irradiation of the polystyrene surface incorporates
carboxyl groups capable of ionic interactions with positively charged groups on the
biomolecules (Gibbs, 1995a). Resultantly, the binding capacity is greatly increased to
approximately 400-500 ng IgG/cm^, due to the fact that ionic interactions require that
smaller portions of the molecule be in contact with the surface to achieve stable
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immobilisation (Gibbs, 1995a), Also, when polystyrene plates were coated with
adhesive polyphenolic protein purified from the mussel Aulacomya ater\ the capacity
of the plates to bind antigens such as hCG was enhanced significantly (Burzio et al.,
1996).
However, there is a significant loss of biological recognition following immobilisation
of antibodies and antigens to surfaces (Lu et al., 1996; Butler, 1992). Covalent
immobilisation of antigen may lead to loss of one or more epitopes through formation
of the covalent linkage or steric hindrance, whilst passive adsorption may lead to
epitopes being sterically buried (Butler, 1992). When antibodies are covalently
attached to supports, their specific binding capacity is usually less than that of soluble
antibodies (Lu et al., 1996). The reason for this reduction is attributed to the random
orientation of the antibody, resulting in the exclusion of the antibody binding site in the
Fab region (Lu et al., 1996). After passive adsorption, it has been reported that <3.0%
of the binding sites of monoclonal antibodies and approximately 5-10% of those of
polyclonal antibodies were capable of capturing antigen (Butler et al., 1992). Lu et al.
(1996) have reported on a number of methods to alleviate the problem of random
orientation of IgG antibodies. Firstly, proteins A/G can be used to bind the antibody
via the Fc region, thus leaving the antigen binding sites free, or alternatively, antibody
can be coupled to the solid support via an oxidised carbohydrate moiety associated
mainly with the Fc region. Finally, monovalent Fab’ fragment may be bound to the
insoluble support via a sulphydryl group in the C-terminal region of the fragment.
Oriented immobilisation can also be achieved using antiglobulin or avidin-coated
surfaces to bind biotinylated antibody, the former method giving a higher percentage of
active sites per well (in some cases >70%) (Butler et al., 1992). However, the actual
number of sites is low, resulting in similar or fewer numbers of active sites per well
57

when compared to the avidin-biotin method or passive adsorption (Butler et al., 1992),
Antibodies immobilised by the avidin-biotin method generally gave the highest number
of binding sites per well when compared to antibodies immobilised by the other two
methods (Butler et al., 1992). When compared to covalent immobilisation, antibodies
immobilised via the avidin-biotin bridge also showed increased activity (Peterman et
al., 1988; cited in Butler et al., 1992).
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1.9 Alternative Immunoassays

1.9.1 Immunosensors
Immunosensors are defined as “analytical devices that detect the binding of an antigen
to its specific antibody by coupling the immunochemical reaction to the surface of a
device known as a transducer” (Gizeli and Lowe, 1996). An immunosensor is a form
of biosensor, in which the antigen or antibody represents the sensor molecule, with the
signal transducer providing an indication that the ligand has bound to the sensor
(Morgan et al., 1996). Four main types of transducer have been used, exploiting
changes in electrochemical, mass, heat or optical properties (Morgan et al., 1996).

Direct immunosensors involve the direct detection of the antibody-antigen reaction in
real time, whereas indirect immunosensors involve the use of a label to detect the
antibody-antigen reaction (Gizeli and Lowe, 1996; Morgan et al., 1996). However,
Morgan et al. (1996) suggest that the latter is not a true immunosensor. True
immunosensors are attractive alternatives to conventional immunoassay, allowing
rapid, real-time monitoring of antibody-antigen reactions in homogeneous formats, the
most sensitive immunosensor being in the order of 2 x 10’'^ mol/l for hepatitis B
surface antigen measurement in serum (Morgan et al., 1996). The latest addition to the
immunosensor family involves the use of optical tweezers to detect the antibodyantigen reaction, however, it is not a true immunosensor, since the system does not
allow real-time monitoring. Optical tweezers are focussed laser beams used to trap and
remotely manipulate dielectric particles, and have recently been used to measure the
force required to separate antigen-antibody bonds in a competitive immunoassay for
BSA (Helmerson et al., 1997). In the assay, the optical tweezers is used to trap
polystyrene microspheres coated with antigen and then pull the microspheres away
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from a silanized glass coverslip coated with specific antibody. Throughout, the average
force applied by the optical tweezers to break the antigen-antibody bonds and pull the
microspheres away from the surface is measured. When free antigen is applied to the
system, the force required is decreased in inverse proportion to the amount of antigen
added, thus allowing a standard curve to be prepared. With this competitive or
displacement-type system, 1.45 x 10'*^ mol/l of BSA could be measured after a 2-h pre
incubation. However, the authors would need to verify this detection limit using real
samples.
Similarly, single antigen-antibody recognition events can be detected using atomic
force microscopy (AFM) (Davies et al., 1994). In this technique, a surface of interest is
moved past a very small tip attached to a flexible cantilever; the bending of the
cantilever as the tip rises and falls gives an indication of the surface roughness or
topography (Kricka, 1997). Davies et al. (1994) used AFM to compare microtitre
wells coated with passively absorbed anti-ferritin antibody with those coated with
biotinylated anti-ferritin antibody linked via streptavidin. Both types of surface were
analysed before and after incubation with ferritin antigen, with the extent of ferritin
binding being represented by an increase in surface roughness. Their studies, while
showing the advantages of using the latter method for coating antibodies to
polystyrene, also demonstrated the potential application of AFM in quantitative
analysis. Recently, Perrin et al. (1997) realised this potential, adapting the AFM to the
quantitative analysis of ferritin. Silicon wafers were covalently coated with anti-ferritin
antibodies to a surface density of 1.4 ng/mm^. To demonstrate ferritin binding, an
ELISA was performed on the coated wafers using an alkaline phosphatase-labelled
anti-ferritin antibody as detector and /;NPP as substrate. Subsequently, the suitability
of AFM to quantitative measurements was demonstrated using coated wafers
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incubated with a range of ferritin concentrations, followed by scanning with the AFM.
As expected, the authors noticed that the surface roughness of the wafers increased in
direct proportion to the concentration of ferritin added. However, at this stage of
development, the sensitivity of the AFM immunoassay does not compare well with
conventional ELISA, i.e., 60 ng/ml v 1.2 ng/ml.

1.9.2 Novel homogeneous immunoassay
Recently, MeyerhofiF et al. (1995) described a non-separation electrochemical enzyme
immunoassay (NEEIA) for detecting marker proteins in undiluted blood using a goldcoated microporous membrane. The gold coating served simultaneously as a solid
phase for immobilising the capture antibody and an amperometric detector for
monitoring, via an oxidation or reduction reaction, the amount of enzyme product
generated immediately adjacent to the gold surface. In the assay, analyte is incubated
simultaneously with horseradish peroxidase-labelled antibody on the gold side of the
membrane, resulting in the formation of a sandwich on the surface during a fixed
period of incubation. The substrate is then introduced through the back side of the
porous membrane, encountering the immobilised enzyme-conjugate first. During the
shon electrochemical measurement period after substrate addition (1 min), very little
substrate diftuses into the bulk solution, hence, no separation step is required.
As discussed earlier, Merenbloom and Oberhardt (1995) developed a novel
homogeneous immunoassay for whole-blood samples using thrombin as the label.
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1.9.3 Dual and multianalyte immunoassays
Immunoassay systems generally measure only one analyte type in a sample, however,
the potential advantages of shortened overall assay times, use of less sample, and
reduction in reagent costs has spurred authors to develop immunoassays that
simultaneously measure two or more analytes.
Blake et al. (1982) developed a classical competitive enzyme immunoassay that
simultaneously measured the thyroid hormones,

T3

and

T4,

in one tube. This

simultaneous format was facilitated by the use of two different enzyme systems that
generated

products

distinguishable

by

absorption

spectrophotometry

Alkaline

phosphatase and P-galactosidase were used as the labels and were detected using
phenolphthalein monophosphate and 6>NPG, respectively. When the substrates were
hydrolysed, they generated products with different spectral characteristics. In fact, the
absorbance of phenolphthalein at 420 nm was only 1.7% of its absorbance at 540 nm,
while o-nitrophenol had <0.7% of its maximum absorbance (-420 nm) when studied at
540 nm. Although this model demonstrated the principle of simultaneous immunoassay
very well, it did have one minor flaw. Due to the differing pH optima of the two
enzymes, colour development had to be carried out using separate incubations.
However, this is a flaw with the model system and not with the principle itself, and
could potentially be rectified using enzymes with similar pH optima. The authors also
suggest that the model could be expanded so that more than two analytes could be
measured simultaneously.
Macri et al. (1992) developed a sandwich enzyme immunoassay for the simultaneous
measurement of a-fetoprotein and free-P hCG using alkaline phosphatase and
peroxidase as labels. However, while all the steps of the sandwich assay were carried
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out simultaneously, colour development again required separate incubations. In any
case, the assay did reduce reagents costs and sample volume requirements.
In 1992, Hoshino and Miyai developed a simultaneous homogeneous enzyme
immunoassay for the measurement of ferritin and a-fetoprotein using a single
incubation, in which sample was mixed with two specific horseradish peroxidaselabelled antibodies and with substrate. No separation was required, since only antibody
aggregates showed catalytic activity. From separate dose-response curves for both
analytes, the authors were able to establish absorbance cut-off points for the
simultaneous assay of samples, below which both analytes were within normal limits
(<20 ng/ml for a-fetoprotein and <200 ng/ml for ferritin) and above which one or both
analytes were high. Since the individual absorbances of 20 ng/ml of a-fetoprotein and
200 ng/ml of ferritin were 0.015, the first cut-off point was 0.015. Therefore, any
samples giving absorbances below 0.015 in the simultaneous assay were considered
negative. If a sample gave an absorbance >0.03, it was considered positive, because
one or both analytes must be high. Samples giving absorbances between 0.015 and
0.03 were treated as suspicious, since both analytes may be normal or one may be
above the cut-off point of 0.015. For positive and suspicious samples, both analytes
were measured separately to determine which parameter was increased. Therefore,
while the assay only allowed semi-quantitative analysis, it did prove a useful screening
method for the two tumour markers.
As discussed earlier, Hendrickson et al. (1995) developed a solid-phase two-site
sandwich immunoassay for the simultaneous measurement of hTSH, hCG, and (3galactosidase using three specific monoclonal antibodies as capture and three specific
oligonucleotide-labelled monoclonals (Hendrickson et al., 1995).
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1.10 Optimisation of Immunoassay

1.10.1 Development of a two-site sandwich immunoassay

1.10.1.1 Optimisation of antibody concentrations
Firstly, one needs to determine the optimum concentration for coating the capture
antibody to the solid phase. To do this, a range of antibody concentrations are used for
immobilisation and standard curves are prepared at each concentration using a constant
excess of labelled antibody (Kemeny, 1992; Gibbs, 1995b). When the standard curves
are plotted (concentration v’s specifically bound signal), one should notice an increase
in steepness of the curves with increasing antibody concentration, until an antibody
concentration is reached above which no improvement in signal is achieved (Figure
1.10 1). This may be due to the fact that excess reagent concentrations prevail, in
which case further increases serve only to increase the background signal (non-specific
binding) (Micallef and Ahsan, 1994).
Alternatively, the binding capacity of the solid phase may have been reached. For
instance, the optimal concentration for coating antibody to plastic by passive
adsorption typically lies between 0.4 to 10 pg/ml. Further increases leads to unstable
multilayer formation from protein-protein interactions, thus leading to a reduction in
assay sensitivity and precision (Kemeny, 1992). Once the coating concentration has
been established, the same procedure can be used in the optimisation of conjugate
concentrations.
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Antigen concentration
Figure 1.10.1 Determination of the optimum coating concentration for primary
antibody.

Micallef and Ahsan (1994) used a slightly different approach to optimising the
concentration of antibody used to coat magnetic particles. Various concentrations of
immobilised antibody were reacted with excess labelled antibody in the presence of
zero analyte and at the highest concentration of analyte specified to be measured
(Figure 1.10.2). As before, the specific signal for the highest standard reaches a
maximum value with increasing antibody concentration (in this case excess reaction
concentrations prevail). Further increases in antibody serve only to increase non
specific binding, leading to a reduced signal-to-noise ratio and decreased sensitivity.
Again, the labelled antibody may be similarly tested at serial dilutions using the
optimised immunoextractant concentration. This approach has been used by a number
of workers to optimise concentrations of antibody for use in two-site immunoassays
(Noe et al., 1992; Dhahir et al., 1992).
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Figure 1.10.2 Titration of coating antibody for use as an imnnmoextractant in a twosite sandwich assay.

1.10.1.2 Method of immobilisation
As discussed earlier, the immobilisation method is also of importance when optimising
immunoassays. Passive adsorption and most covalent methods render a high
percentage of bound antibodies inactive. Alternative methods, in which there is
oriented immobilisation of the antibody molecules, may generate a higher number of
functional sites, e g., biotin-avidin systems, protein A/G, etc.

1.10.1.3 Incubation conditions
To help ensure accuracy in the measurement of samples, it is advisable to use a
calibrant matrix which is identical to (Papoian et al., 1991), or closely resembling
(Dhahir et al., 1992), the sample matrix with respect to composition and pH. If buffer
is to be used as calibrant matrix, one should at least ensure that the pH approximates
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that of the samples to be measured. However, it is likely that use of such a buffer in
conventional two-site sandwich immunoassay will lead to poor comparison between
sample and standard, since there are differences in composition. For the incubation of
conjugate antibody, a buffer with pH between 6 and 9 should be used, since antigenantibody reactions normally take place within this range (Kemeny, 1992).
To achieve maximum signal, it is usual to incubate for sufficient time to allow all
reactions to achieve or approach equilibrium. Generally, the higher the incubation
temperature used, the shorter the times required. For example, Papoian et al. (1991), in
a sandwich ELISA for IL-3, performed the incubations for both analyte and conjugate
at 37°C for 1 h, while Noe et al. (1992) incubated analyte at room temperature for 4 h
and conjugate overnight at 4°C in a sandwich ELISA for erythropoietin.
As described earlier, analyte and labelled antibody can be reacted simultaneously with
immunoextractant in a single step or, alternatively, analyte and labelled antibody may
be incubated sequentially using two separate reactions. The former saves on time, but
it does have problems with the hook effect (Nomura et al., 1983).

1.10.2 Development of a limited-reagent assay
Selection of the appropriate antibody and labelled analyte concentrations is performed
by making serial dilutions of both, and testing the combinations of each antibody
dilution with every labelled analyte dilution in the presence of zero standard and at
anticipated lowest and highest analyte concentrations (Micallef and Ahsan, 1994). The
initial optimum concentrations are those giving the greatest, and most reproducible,
changes in bound signal with increasing analyte concentrations (Figure 1.10.3), and the
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final concentrations selected are those giving the best precision in the clinical
diagnostic range (Micallef and Ahsan, 1994).

Figure 1.10.3 Antibody dilution and displacement curves at a fixed concentration of
labelled analyte. More curves are preparedfor other labelled analyte concentrations.

Generally, workers prepare antibody dilution curves without added unlabelled analyte
and pick the antiserum dilution giving approximately 30-50% (Bailey, 1994) or 4050% (Parker, 1990) binding of labelled analyte, since displacement of the label by a
small increment of unlabelled analyte is usually at its greatest here (maximal slope at
zero-dose response). For competitive immunoassays using radioactive label, the
radioactive antigen giving about 8,000 to 10,000 cpm is generally used (Parker, 1990;
Bailey, 1994), whereas in immunoassays with antigen-enzyme conjugates, the goal is
to obtain about 40-50% binding in uninhibited samples with enough enzyme activity to
detect decreases in binding down to about 5% or less (Parker, 1990).
Ekins (1991) suggests that assays constructed in such a manner are likely to give
adequate sensitivity and an acceptable working range, but are formulated without
regard for the effect antibody concentration has on assay precision and sensitivity. He
suggests preparing antibody dilution curves (similar to above) using 1) zero standard
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and 2) a small increment of unlabelled analyte ([AA]), sufficient in magnitude to cause
significant displacement of the resulting antibody dilution curve. Each point of the
antibody curve is determined in replicates of five to ten. The labelled analyte
concentration is fixed and represents the lowest usable concentration needed to register
a measurable signal down to, for example, 1% binding of label. The curve obtained is
similar to above (Figure 1.10.3), but without high standard. Ekins indicates that the
antiserum dilution giving the greatest displacement should not be used without regard
to the (im)precision, since reproducibility of the zero-dose response may be poor here.
He suggests plotting 5b/Ab (standard deviation in measuring bound signal at zero dose
divided by the change in bound signal due to the displacement by unlabelled analyte) as
a function of bo (the signal bound at zero dose) (Figure 1.10.4). From this curve, an
antiserum concentration can be chosen which gives a low standard deviation in the
measurement of zero dose (but with good displacement).

Figure 1.10.4 Curve representing the quotient SCAh plotted as a function of ho. The
value of ho at which SfAh is minimal (‘‘x’' on graph) indicates the antibody dilution
giving maximal sensitivity (Ekins, 1991).
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1.11 Validation of Immunoassay

1.11.1 Specificity
To test the specificity of an assay system, dose-response curves are constructed in the
presence of the analyte and potential cross-reactants tested at concentrations greater
than likely pathophysiologic concentrations (Micallef and Ahsan, 1994). For example,
Ko et al. (1992), in a non-competitive ELISA for IL-8, tested serial dilutions ranging
from 1 pg/ml to 0.1 ng/ml of recombinant IL-8 (rIL-8) and potential cross-reactants
such as monocyte chemotactic and activating factor (MCAF), rIL-la, and recombinant
tissue necrosis factor (rTNF). Brailly et al. (1994) used the same procedure in a twosite ELISA for IL-6, but they also tested potential cross-reactants added at 100 pg/1 to
rIL-6

solutions.

The latter procedure is particularly important for two-site

immunoassays, since a cross-reactant that binds only one of the two antibodies will
give little or no assay response when presented alone, but may reduce the response of
analyte if simultaneously present in sufficiently high concentrations (Micallef and
Ahsan, 1994)
For competitive immunoassays, serial dilutions of analyte and cross-reactant may also
be tested as above, with cross-reactivity expressed as the percentage ratio of
concentrations of analyte and cross-reactant that produces 50% displacement of tracer
(Carstens et al., 1997; Luppa et al., 1995).

1.11.2 Sensitivity (detection limit)
The determination of the detection limit (sensitivity) also incorporates an assessment of
the reproducibility (within-run precision) of an assay. For example, Brailly et al. (1994)
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assayed a range of IL-6 standard concentrations in replicates of twelve, thus allowing a
calculation of the signal coefficient of variation (%C.V.) for each concentration. The
resultant information was then used to prepare a precision profile by plotting the
%C.V. (y-axis) against the analyte concentration (x-axis), thus allowing determination
of the working range of the assay. To calculate the minimum detectable dose, the
authors used the dose-response curve, extrapolating from the y-axis at the signal equal
to non-specific signal (blank) plus two standard deviations (S.D.). However, Micallef
and Ahsan (1994) recommend a factor of three be universally adopted.
The assay detection limit, which is defined as the (im)precision in measurement of the
zero-dose response, is now widely accepted as the only valid indicator of immunoassay
sensitivity (Ekins and Chu, 1991). The authors claim that the slope of the doseresponse curve as an indicator of sensitivity is misleading, since a curve of lower slope
could possibly have a lower imprecision of zero-dose response, and so a lower
detection limit, than a curve of greater slope.
Ekins and Chu (1991) indicate that the sensitivity of competitive immunoassays are
limited primarily by the affinity of the antibody, with the specific activity of the label of
secondary importance. Assuming that 1) the error of signal measurement to be zero
(label of infinite specific activity), 2) the use of

as label with the radioactivity being

counted for 1 min, 3) the radioactivity of the antibody-bound labelled analyte is
measured, and 4) the experimental error in the measurement of the bound fraction
(5ro/Ro)

is 1%, the potential sensitivity attainable in such an assay is 5b/KRo, where

5b/Ro represents the error in the measurement of zero-dose response (Ro). For
example, if K is 10^^ 1/mol, maximal assay sensitivity is 10'^'^ mol/l or ~6 x 10^
molecules/1. According to Ekins and Chu (1991), it is near impossible in practice to
achieve sensitivities greater than about 10^° molecules/1 using a competitive approach,
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assuming an upper limit of antibody affinity at 10^^ 1/mol, irrespective of the nature of
label used.
From the literature, the practical limit of competitive immunoassays appears to be in
the picomolar range. Luppa et al. (1995) achieved a detection limit of 55 pmol/1 (2.5
fmol/well) in an immunoassay for total estrone, while Ogbonna et al. (1995), in their
competitive immunoassay for apolipoprotein BlOO, attained a detection limit of 4.0
pmol/1 or 400 amol/tube. However, since these authors failed to record the affinities of
the antibodies used, it is difficult to assess how close these assays came to Ekins’ and
Chu’s (1991) theoretical limits. Carstens et al. (1997), in a radioimmunoassay for
urodilatin in human urine, measured 500 amol/tube. This corresponds to a urine
concentration of 7.5 pmol/1, if 400 pi of urine is extracted and resuspended in 600 pi of
assay buffer, using 100 pi for assay. Applying the affinity of the polyclonal antibody
used (1.05 X 10*' 1/mol) to the model as proposed by Ekins and Chu (1991), the
theoretical limit is ~10'^^ mol/1 or 0.1 pmol/1, which is seventy-five times lower than the
limit achieved. Interestingly, Helmerson et al. (1997) measured as low as 1 fmol/1 (1
zmol/assay) using an optical tweezers-based competitive immunoassay for BSA. While
this appears to be lower than theoretical limits, the antibody affinity was not stated.
According to the models proposed by Ekins and Chu (1991), the potential sensitivity
of a non-competitive immunoassay is given by (Ro/[Ab]K)(5Ro/Ro), with Ro in this
case representing the labelled antibody misclassified as bound, commonly referred to as
“non-specifically bound” antibody. The authors stress the importance of minimising
non-specific binding and using high affinity antibodies with non-isotopic labels of high
specific activity in order to achieve the maximal potential sensitivity.
In accordance with the theoretical model as proposed by Ekins and Chu (1991), the
assays with the lowest detection limits are indeed the non-competitive reagent-excess
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assays. In 1982, Ishikawa et al measured as little as 0.2 amol of ferritin (1.33 x 10'^^
mol/1), 2.4 amol of IgE (1.6 x lO'*'^ mol/1), and 5.7 amol of TSH (3.8 x lO'*'* mol/1),
using antibody-coated polystyrene balls and affinity-purified Fab’-|3-galactosidase
conjugate in a sandwich format. Using antibody-coated glass balls in a similar format,
Ruan et al. (1987) attained even better sensitivities, measuring 1 zmol of ferritin (2 x
10'^^ mol/l) and 0.03 amol of IgE (6 x 10'*^ mol/l). Hashida and Ishikawa (1990) also
measured 1 zmol of ferritin (3.33 x 10'*^ mol/l), but using a more complicated format
called immune complex transfer two-site immunoassay.

Ferritin was reacted

simultaneously with affinity-purified dinitrophenyl biotinyl anti-ferritin IgG and affinitypurified anti-ferritin Fab’-(3-galactosidase conjugate. The complex formed was trapped
onto anti-dinitrophenyl group IgG-coated polystyrene balls. After washing the balls to
remove excess conjugate, the complex was eluted from the balls using an excess of
aN-dinitrophenyl-L-lysine and transferred to streptavidin-coated balls. In this way, the
non-specific binding was reduced with a lesser decrease in specific binding, giving
improved sensitivity when compared to the previous assay using IgG-coated
polystyrene balls (Ishikawa et al., 1982). In addition, the assay showed little ill-effects
when 5 |j.l and 10 |il of serum was added to the reaction mixture. The authors suggest
that even better sensitivity could be achieved through the use of a label with higher
specific activity and another transfer of the complex. However, it would be of interest
to see how these non-competitive immunoassays would fare with real samples.
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1.11.3 Precision
Within-run and between-run precision are simply assessed using samples analysed in
several replicates, usually at low, medium, and high concentrations of analyte (Luppa
et al., 1995; Ogbonna et al., 1995; Tanebe et al., 1992; Dhahir et al., 1992).

1.11.4 Accuracy
Generally, samples, especially biological samples (serum, plasma, cerebrospinal fluid,
urine), constitute complex mixtures, with certain components of the matrix possibly
inteifering non-specifically with the immune binding reaction of the assay (Baker et al.,
1985). These interferences are particularly problematic when standards are prepared in
buffer diluents (Noe et al., 1992; Luppa et al., 1995; Tanebe et al., 1992), since there is
no guarantee that such a matrix will behave identically to the sample matrix.
Preferably, the calibrant matrix should be identical to the fluid in the samples to be
tested (Papoian et al., 1991), as the assay response may vary in different media. As an
alternative, one could use a closely resembling matrix, for example, Dhahir et al.
(1992) used bovine serum as calibrant matrix in a two-site sandwich assay for the
measurement of proinsulin in human serum
To determine whether the system can accurately measure analyte in samples when
compared to standard, one can perform recovery, linearity, and comparison studies.

1.11.4.1 Recovery
For study of analytical recovery, workers usually add graded doses of calibrant
spanning the dose range of the assay to samples (Bugari et al., 1990, Dhahir et al.,
1992; Noe et al., 1992). When the samples are analysed, the observed results should
equal the endogenous concentrations plus the amounts of calibrant added. Recovery is
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then calculated by dividing the observed value by the expected value and multiplying
by 100. A mean recovery of -100% indicates that the matrices of the samples and
standards are equivalent (absence of matrix effects) (Baker et al., 1985).
This method is likely to give false recovery results, since the endogenous concentration
is measured using the assay under investigation, with recovery assumed to be 100%.
For example, Bugari et al. (1990) used their system to measure the endogenous
concentration of lutropin in a serum pool (4.4 I.U./l) and added 3.125 I.U. of lutropin
per litre to give an expected value of 7.525 I.U./I. Subsequently, the measured value
was 7.2 I.U./l, giving a recovery of 90%. However, if for example, the recovery
associated with the endogenous concentration was initially 80% (actual 5.5 I.U./l),
then the actual recovery would only be 83.5%.
A more correct approach would be to use sample matrix devoid of analyte under
investigation (Aubin et al., 1997).

1.11.4.2 Linearity
Simply, samples may be progressively diluted in calibrant matrix and analysed to
calculate the amount of material present. Any substances present in the samples that
affect assay response, but are not identical to the calibrant, may give sample and
standard dose-response curves that are non-parallel (Micallef and Ahsan, 1994). There
are several ways to assess parallelism. Firstly, from the measured concentration in the
undiluted sample, one can calculate the expected values of the diluted samples and plot
the expected versus measured values (Bugari et al., 1990). The resultant plot should
give a straight line of negligible intercept and a correlation coefficient (r) of 1.00.
Alternatively, one may plot the effective sample volume (x-axis) against the measured
concentration on the y-axis (Luppa et al., 1995; Tanebe et al., 1992), with the points
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obtained falling on a straight line of negligible intercept. Any deviation from linearity at
higher volumes (lower dilutions) would clearly indicate that the sample volumes or
dilutions routinely determined should be limited to those safely within the linear region
(Micallef and Ahsan. 1994).

1.11.4.3 Comparison with reference methods
A number of samples are analysed and compared to an established reference method
using regression analysis. While Luppa et al. (1995) and Burgi et al. (1988) used
sample numbers greater than thirty, others have failed to use statistically significant
numbers of samples. Ogbonna et al. (1995) used only ten samples for comparison
purposes with an immunoturbidimetric assay, while Noe et al. (1992) used only
seventeen for correlation with RIA.
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1.12 Some Interferences in Immunoassay

Pesce and Michael (1992) outlined the common interferences associated with
immunoassay and divided them into exogenous and endogenous causes. The
exogenous interferences are due to effects before the test reaction occurs, whereas
endogenous interferences are due to materials inherent in the biological test solution.
Exogenous

interferences

include

sample

collection

reagents,

for

example,

anticoagulants such as heparin and EDTA. The effects of these reagents can be
observed by performing recovery studies with added interferent. In addition, the
authors identify solid-phase binding as a possible cause of exogenous interference, in
that binding of antigen or antibody to a surface may change the properties of that
surface, thus leading to non-specific binding. Graves (1988) showed that the non
specific binding of rabbit IgG to a protein-coated surface was highly charge dependent,
with binding being high to positively charged surfaces. Also, incomplete saturation of
solid-phase binding sites for antigen and antibody may lead to non-specific binding,
thus reagents may need to be added to block these vacant sites. A study by Pratt and
Roser (1989) compared casein, BSA, and newborn calf serum for their ability to block
unoccupied sites on polystyrene solid phase. Results showed casein to be the most
effective blocking agent, a result which was later confirmed by Esser (1991).
Heterophilic antibodies, which represent one of the endogenous interferences, are
antibodies present in serum/plasma samples capable of reacting with various species of
immunoglobulins (Kohse and Wisser, 1990; Levinson, 1992). Kohse and Wisser
(1990) and Levinson (1992) outlined the possible mechanisms of interference by these
antibodies in immunoassays. In a double antibody method, the heterophilic antibody
can promote binding between the first and second antibodies, even in the absence of
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analyte, leading to an erroneously high result. On the other hand, the heterophile
antibody may bind only one antibody, thus sterically hindering binding of the analyte to
this antibody. An erroneously low value results In addition, heterophilic antibodies
may also cause problems in competitive immunoassay when double-antibody solidphase separation systems are used (Boscato and Stuart, 1988; Kohse and Wisser,
1990). Presumably, the presence of the heterophilic antibody in the sample could lead
to inhibition of antibody binding to the second antibody immobilised to solid phase,
thus leading to reduced bound tracer and an erroneously high analyte value. The
interference caused by heterophilic antibodies may be eliminated using a non-specific
immunoglobulin from the animal species used to raise the antibodies. However, this
does not always work. Polyclonal mouse IgG and polymerised monoclonal IgG failed
to eliminate interferences from heterophilic antibodies in a two-site assay for creatine
kinase MB (CKMB) using two monoclonal antibodies (Vaidya and Beatty, 1992).
When the authors analysed eighty-one samples using an intact capture anti-B antibody
and intact anti-CKMB-P-galactosidase conjugate, eighteen out of eighty-one samples
gave falsely high CKMB values due to heterophilic antibodies. Addition of polymerised
monoclonal IgG and polyclonal mouse IgG failed to eliminate the false positive results.
However, when the intact IgG-enzyme conjugate was replaced by an F(ab’)2conjugate, fourteen of the eighteen samples gave values within the normal range. Use
of the polymerised or polyclonal IgG along with the F(ab’)2-enzyme conjugate gave
normal results for all samples. Therefore, the results of the study indicate that the
heterophilic antibodies largely had specificity for the Fc region of the monoclonal
antibodies. However, the use of fragmented antibodies would not always eliminate
heterophilic antibody interferences, since some have been shown to be directed against
epitopes residing on the Fab region (Levinson, 1992).
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Some other endogenous interferences include those due to rheumatoid factors and
autoantibodies present in serum or plasma. Rheumatoid factors are IgM-type
antibodies that bind to multiple antigenic determinants on the Fc portion of IgG
(Levinson, 1992, Kohse and Wisser, 1990). The consequences of this binding in
relation to immunoassay have been discussed earlier (“Antibody fragments”). In
addition, some individuals can produce autoantibodies to the test analyte, the most
frequently occurring antibodies being those to thyroglobulin, with antibodies against T3
and T4 occurring less commonly (Kohse and Wisser, 1990). Such antibodies can lead
to erroneously high or low hormone concentrations when measured using competitive
immunoassay depending upon the separation method used (Kohse and Wisser, 1990).
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1.13 Column-Based Flow-Through Immunoassay

Although immunoassay techniques offer the advantages of selectivity and sensitivity,
they have the disadvantage in that they usually require prolonged incubation times,
since the rate of antigen-antibody interaction is diffusion dependent. To circumvent this
limitation, many have turned to affinity chromatography, thus reducing the contact
time between antigen and antibody (de Alwis and Wilson, 1985; Lejeune et al., 1990;
Hage and Kao, 1991; Freytag et al., 1984; Janis and Regnier, 1989; Cassidy et al.,
1992; Nilsson et al., 1994, Kronkvist et al., 1997). In addition, many column-based
immunoassays are automated, thus reducing operator input and eliminating the need
for experienced personnel.
de

Alwis

and

Wilson

(1985)

designed

a

high-performance

immunoaffmity

chromatography (HPIAC) sandwich ELISA for the measurement of mouse anti-bovine
IgG using a flow-through immunoreactor packed with bovine IgG immobilised on
Reactigel-6X. To carry out the assay, a standard was injected into a flowing stream of
assay buffer and carried through the immunoreactor to waste. This injection was
followed by two injections of a goat anti-mouse IgG-glucose oxidase conjugate spaced
2 min apart. Again, excess material was carried to waste by the flowing stream.
Subsequently, three aliquots of 1% glucose were injected at 3-min intervals and the
resulting product (H2O2) was diverted to an amperometric detector. The output from
the detector was processed and the peak area was used as the basis of analysis. Such
analysis took 15 min. Minutes after the last addition of substrate, the column was
exposed to disruption buffer to remove analyte-second antibody conjugate, followed
by assay buffer to equilibrate the column. This disruption and equilibration process
took approximately 15 min. The lower limit of detection of the assay was in the
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femtomolar range when the standards were prepared in buffer or in 6 g/dl bovine
serum albumin in buffer, however, when control serum was used the limit increased to
1 pmol or 3.33 x 10'^ mol/1.
In the column-based sandwich immunoassay designed by de Alwis and Wilson (1985),
the advantages of the chromatographic process appears only in the first step, i.e.,
ligand binding by a large excess of antibody solid-phase, whereas the second step
(addition of labelled antibody) is run with a lack of stationary phase excess. This results
in the loss of the chromatography advantages at the second step. Consequently, several
additions of the labelled antibody are required for reproducible binding. This lead
Lejeune et al. (1990) to design an automated reversible antibodies capture
immunoassay (RACIA) for human growth hormone. Their system used an affinity
column packed with two superimposable gels, the first labelled with a phosphonic
group (a ligand of phosphatase) and the second one with aminophenyl thiogalactoside
(a (3-galactosidase ligand). Two anti-human growth hormone antibodies, conjugated to
p-galactosidase and alkaline phosphatase and directed at different epitopes on the
antigen, were then passed through the column. A standard prepared in buffer
containing 0.5% or 6% BSA was passed through the column, resulting in the binding
of antigen to the antibody-alkaline phosphatase conjugate in the first part of the
column. Addition of an excess of mineral phosphates displaced the enzymatically
labelled antibody-antigen complex, which was then captured by the excess antibody in
the second part of the column. After elution using an alkaline buffer, the complexes
were collected and assayed for phosphatase activity using amplified detection. The
revelation time was 3.25 h. During the elution process, the column goes back to its
native state and is ready to receive antibody-enzyme conjugates directed against the
same or different analytes. The optimised system allowed the measurement of human
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growth hormone in the range of 0.1 amol to 100 fmol in a 4-h time period overall.
However, it remains to be seen whether such sensitivity could be attained using real
samples.
To improve on the sensitivity obtained by de Alwis and Wilson (1985), Hage and Kao
(1991) used HPIAC to develop a sandwich assay for parathyroid hormone (PTH)
using chemiluminescent detection. In this method, a standard prepared in plasma and
acridinium ester-labelled anti-(l-34 PTH) antibodies were injected onto a column
containing anti-(44-68 PTH) antibodies. The column was then washed, with excess
reagents going to waste. After desorption with elution buffer, the labelled antibody was
combined with alkaline peroxide reagent in a post-column reactor and the resulting
light production was measured. The column was then switched back to assay buffer
and allowed to equilibrate before the next standard was added. The assay took 1 h 6
min per sampling, allowing 1 h for pre-incubation of the standard and labelled antibody
and 6 min per plasma injection. The limit of detection of the assay was 16 amol, which
equals 2.4 x 10'^^ mol/l using a 66 pi assay volume.
Freytag et al. (1984) designed a single-antibody non-competitive aflfinity-columnmediated immunoassay (ACMIA), which could be performed on the DuPont aca® III
discrete analyser. To determine digoxin, standards prepared in drug free serum were
mixed with an anti-digoxin-P-galactosidase conjugate in the sample cup. After a 10min pre-incubation at room temperature, an aliquot of each mixture was aspirated and
passed through a disposable affinity column containing immobilised analyte. The
enzyme activity that passed through the column was quantified using oNPG as
substrate, with the enzyme activity being measured as the rate of change in absorbance
at 405 nm. Therefore, the concentration of digoxin was directly proportional to
enzyme activity. The optimised assay using oubain resin, F(ab’)2-P-galactosidase
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conjugate, and a flow rate of 34 fil/s had a total analysis time of 18 min, giving a limit
of detection for digoxin of 0.2 mg/1 (2.56 x 10’^ mol/1) using a 200 |j.l volume.
In 1989, Janis and Regnier made use of two columns, an affinity and a reverse-phase
chromatography (RPC) column, in an automated non-competitive system called dual
column immunoassay (DCIA). The immunoaflfinity column was prepared by reversible
adsorption of antibodies on a column with covalently immobilised protein G. The use
of protein G means that the columns could be used for a wide range of immunoassays
(universal support). For transferrin quantitation, rabbit anti-human transferrin was
injected first onto the protein G column, followed by an injection of serum sample or
standard containing transferrin. The antigen was then desorbed using elution buffer and
quantitated by RPC. Loading buffer was used to equilibrate the protein G column. The
complete cycle from the addition of antiserum to quantitation of antigen by RPC took
30 min. Since specific antiserum is added prior to antigen injection, one can measure a
different analyte once a cycle is complete. The immunoassay for transferrin had a
detection limit of 0.7 pmol, which equals 3.5 x 10'^ mol/l using a 20 pi volume. The
authors stated that DCIA was more sensitive than conventional immunoaflfinity
chromatography, since the antigen eluted from the first column as a broad peak, was
concentrated on the second more efficient column. When compared to ELISA, the
precision was better, but ELISA was more sensitive. However, the method does allow
one to better discriminate between specific analyte and cross-reactants. As with
ELISA, the procedure also has the potential for multianalyte testing.
Similarly, Cassidy et al. (1992) used a “universal support” to reversibly immobilise any
antibody in an automated competitive assay that also does not require tagged or
labelled molecules.
(KICQA)

In the kinetic immunochromatography sequential addition

immunoassay

for

albumin

or
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transferrin,

specific

antibody

and

standard/serum sample were sequentially added onto a protein A column, followed by
injection of label. The amount of label passing through the column was detected by
absorption in the UV region, giving a direct relationship for calibrants when
absorbance (peak area) was plotted against the concentration of antigen. The label in
KICQA is a known amount of pure antigen and does not possess a tag, e g.,
fluorescent, since the antigen in sample and label contact the antibody at different
times. Once the assay is complete, the antibody-antigen complexes are desorbed using
acidic elution buffer. The authors indicate that the detection limit for human albumin
was 40 ng (1.5 X lO'^'^ mol) using this system, but since they failed to give the sample
volume used, one cannot calculate the molar concentration. However, the authors do
state that this should not be taken as the lower limit of detection for KICQA, since the
limit is subject to the limitations of the detector used and the absence of a tag for the
label. The total assay time is extremely fast, with results available in less than 1 min
(0.9 min).
In 1993, Nilsson et al. designed an automated immunochemical flow-ELISA for aamylase using a sequential competitive format. Calibrant or sample containing aamylase was injected through the injection valve and passed through a column
containing rabbit anti-a-amylase Sepharose CL-4B. This was followed by an injection
of an a-amylase-horseradish peroxidase conjugate onto the column. The conjugate
bound to antibodies not occupied by sample a-amylase. After washing, substrate
solution was passed through the column and product eluting from the column was
measured spectrophotometrically at 540 nm. Bound a-amylase was then eluted from
the column using acidic buffer. A complete cycle took 330 s. The column binding
capacity decreased slightly every time the column was used due to denaturation caused
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by the low pH buffer and substrate solution. Therefore, a standard curve measured on
a fresh column was much higher than a curve measured on the same column after it
had been used for a while. However, the authors state that the shape of the curve does
not change, so that one calibration peak with a known amount of a-amylase was
enough to fit a previously measured curve to the current status of the column. The
nature of calibrants and samples analysed, plus the detection limit of the assay, was not
stated by the authors.
Most of the systems described require regeneration of columns as part of the sampling
cycle, therefore limiting the lifetime of the affinity column and reducing the sample
throughput of the system. Kronkvist et al. (1997) designed an ingenious system which
eliminates the need for time-consuming regeneration. Two different types of assay
were evaluated in their study. The first was based on competitive enzyme
immunoassay, where the analyte (cortisol or budesonide) and a known amount of
alkaline phosphatase-conjugated analyte bind competitively to a limited amount of
antibody. After a 1-h incubation, the standard was injected into the flow where the
antibodies bind to protein G immobilised on the column. The free enzyme conjugate
passing through the column was mixed with substrate from a merging flow and
allowed to react in the post-column reactor. Product was detected downstream by
amperometry or fluorometry. The second enzyme immunoassay was a displacement
assay requiring no pre-incubation step. Alkaline phosphatase-labelled cortisol was
injected into the flow system to overload the capacity of the affinity column, packed
with immobilised anti-cortisol antibodies. After the addition of standard, the displaced
fraction of labelled cortisol was allowed to react with substrate from the merging flow
and detected downstream.
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In both systems, another sample or standard may be added after product has been
detected without the requirement for column regeneration, therefore extending the
lifespan of the column and increasing sample throughput. Resultantly, the displacement
assay for cortisol took about 8 min per analysis. The competitive flow-injection assay
for cortisol and budesonide required at least a 1-h incubation, thus limiting overall
analysis time. However, excluding the pre-incubation, sample throughput was twenty
per hour. Moreover, the conditions for the enzyme reaction for both systems can be
optimised without having to consider the stability of the affinity column, since the
substrate flow does not pass through the column.
Best sensitivity was achieved using the competitive flow-injection immunoassay, which
allowed measurement of 0.02 pmol of budesonide (8 x 10'^ mol/1) using amperometric
detection.

A similar assay for cortisol using fluorescence detection allowed

measurement of 2.5 pmol of cortisol (10'^ mol/1) The displacement assay was not as
sensitive, allowing measurement of only 12.5 pmol of cortisol. However, assessment
with real samples (serum or plasma) was neglected This system does have one major
drawback in that the enzyme reactions are carried out in the presence of sample matrix
components, which may interfere with enzyme activity or detection of product. For
instance, pure plasma interfered greatly with amperometric detection and to a lesser
extent with fluorescence measurements. This limitation can only be overcome using
sample pre-treatment, thus extending the overall analysis time of samples.
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1.14 Project Objectives

• Primarily, to develop an affinity-column-mediated flow-through two-site sandwich
ELISA using ferritin as model analyte. Such a system would be designed with
simplicity and speed in mind, while retaining the performance characteristics
associated with conventional immunoassay systems.
• To ensure the latter through validation studies, e g., recovery, linearity, etc.
• To partially optimise a conventional two-site sandwich ELISA in order to provide
evidence of antigen recognition by the chosen antibody pair. In addition, such study
should demonstrate the potential sensitivities attainable using these antibodies in a
column-based immunoassay.

87

2 Materials

2 Materials

2.1 Equipment

2.1.1 pH meter
Orion model 420A pH/mV/temperature meter (Orion Research (ATI Orion), Boston,
MA. U S A ). The meter is microprocessor-controlled and features pH autocalibration,
sealed keypads and simultaneous temperature display.

2.1.2 Microtitre plate reader
Dynatech MR7000 (Dynatech Laboratories, West Sussex, U.K.). The reader measures
the light absorbance of solutions in each of the 96 wells of a microtitre plate. Reading
is very rapid, with absorbance values available in <1.7 seconds for a single wavelength
and <2.2 seconds for dual readings. Results can be presented graphically or as optical
density matrices via an Epson FX80 compatible dot-matrix printer (Epson America
Inc., Torrance, CA, U S A ). The memory allows storage of fifty user programs and
data from twenty microplates.

2.1.3 Balance
A&D HR200 (A&D Co. Ltd., Tokyo, Japan). The HR200 is a high performance
analytical balance with a resolution of 0.1 mg and a capacity of 210 g.

88

2.1.4 Microtitre plates
Nunc Maxisorp 96-well microtitre plates (Nunc, Roskilde, Denmark). All wells are
within +0.005 absorbance units from the mean and show good homogeneity in the
absorption of IgG - C.V. less than 5% and all results within ±10% from mean.

2.1.5 Water purification system
Millipore-Milli-U 10 (Millipore Corporation, Bedford, MA, U.S.A.). The system
produces grade 2 (according to IS03696/B53978) water directly from deionisation
using a mixed bed ion-exchange resin. Product is low in inorganic ions, dissolved
organic com.pounds, bacteria, and colloidal matter.

2.1.6 Mixer
Denley Spiramix 5 (Denley, Bolney, Sussex, England).

2.1.7 Columns
Disposable polystyrene columns (0.5-2.0 ml) (Pierce, Rockford, IL, U S A.). Supplied
in packages of 100, with 200 polyethylene discs (45 p pore size) and 100 each of top
and end caps.

2.1.8 Centrifuge
The Jouan C4.12 benchtop centrifuge (Jouan Inc., Winchester, VA, U S A.).
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2.2 Chemicals

Merck KGaA, Darmstadt, Germany
• Sodium dihydrogen phosphate (NaH2P04).
• Disodium hydrogen phosphate (Na2HP04).
• Sodium hydrogen carbonate (NaHCOs).
• Sodium carbonate (Na2C03).
• Glycine (C2H5NO2).
• Tris-(hydroxymethyl)-aminomethan (Tris) (C4H11NO3).

BDH Chemicals Ltd., Poole, England
• Hydrochloric acid (HCl) - [density =1.15 g/ml],
• Sodium hydroxide (NaOH).
• Magnesium chloride (MgCb).
• Ethanol (C2H5OH).
• Ethanolamine (C2H7NO) - [density = 1.015 g/ml].
• Acetic acid (C2H4O2).
• Sulphuric acid (H2SO4).

Sigma Chemical Co., St. Louis, MO, U.S.A.
• Diethanolamine (C4H11NO2) - [density = 1.0881 g/ml],
• Polyoxyethylenesorbitan monolaurate (Tween 20).
• Sodium acetate (NaC2H302).
• Sodium chloride (NaCl).
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2.3 Reagents

Sigma Chemical Co., St. Louis, MO, U.S.A.
• Alcohol dehydrogenase (E.C. 1.1.1.1) from equine liver -[1.7 units/mg].
• Diaphorase (E C. 1.8.1.4) from Clostridium kluyveri - [5.4 units/mg],
• (3 -Nicotinamide dinucleotide phosphate ([3NADP).
• /?-Iodonitrotetrazolium violet (INT).
• Bovine serum albumin (BSA), Fraction V.

Pharmacia-Biotech, Uppsala, Sweden
• Cyanogen bromide-activated Sepharose 4B, supplied freeze-dried in the
presence of additives. The product is a pre-activated gel for immobilisation
of ligands containing primary amines, thus it is applicable to the
immobilisation of antibodies. The coupling reaction is spontaneous, rapid,
and convenient.

Fluka Chemie AG, Bucks, Switzerland
• p-Nitrophenyl phosphate (pNPP).
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2.4 Immunoglobulins and Antigen

Biomerieux, Lyon, France
• Mouse monoclonal IgG to human ferritin (clone B8).
• Mouse monoclonal anti-human ferritin-alkaline phosphatase conjugate
(clone B8). The alkaline phosphatase used as label was isolated from calf
intestine.

Calbiochem-Novabiochem, La Jolla, CA, U.S.A.
• Ferritin from human liver

Cork University Hospital, Cork, Republic of Ireland
• Human serum samples
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3 Methods

3 Methods

3.1 Conventional Two-Site Sandwich ELISA for Ferritin

3.1.1 Preparation of buffers

3.1.1.1 pH-adjiisting solutions
• 6 mol/1 HCl. Add 190 ml of concentrated HCl to 810 ml of distilled water (dH20).
• 6 mol/1 NaOH. Dissolve 240 g of NaOH in 1 litre of dH20.

3.1.1.2 Coating buffer
• 0.05 mol/l bicarbonate, pH 9.6. Dissolve 3.44 g of NaHCOs and 0.95 g of Na2C03
in 800 ml of distilled water. Adjust pH with 6 mol/l HCl/NaOH. Make up to 1 litre
with dH20.

3.1.1.3 Wash buffer
•

0.05 mol/l phosphate buffered saline, pH 7.2, containing 0.1% (v/v) Tween 20.
Dissolve 1.69 g of NaH2P04 and 5.11 g of Na2HP04 in 800 ml of dH20. Add 1 ml
of Tween 20 and adjust pH with 6 mol/l HCl/NaOH. Make up to 1 litre with dH20.

3.1.1.4 Assay buffer
• 0.05 mol/l phosphate buffered saline, pH 7.2. Dissolve 1.69 g ofNaH2P04 and 5.11
g of Na2HP04 in 800 ml of dH20. Adjust pH with 6 mol/l HCl/NaOH and make up
to 1 litre with dH20.
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3.1.1.5 Substrate buffer
•

0,1 mol/1 Tris-HCl, pH 9.8, containing 1.5 mol/1 NaCl. Dissolve 12.11 g of Tris and
87.66 g of NaCl in 800 ml of dH20. Adjust the pH with 6 mol/l HCl and make up to
1 litre with dHiO.

3.1.2 General procedure for the measurement of ferritin
1.

Sensitise wells of a microtitre plate with 100 pi of anti-ferritin antibody diluted in
coating buffer. Incubate @ 4°C.

2.

Empty the contents of each well. To wash the wells, add 400 pi of wash buffer
and decant. Repeat the procedure three more times. Finally, blot dry.

3.

Add 200 pi of 1% BSA (1 g/dl dH20) to each well and incubate @ 37“C for 1 h.

4.

Wash the wells as in step 2.

5.

To prepare a standard curve, dissolve ferritin antigen in assay buffer and double
dilute this working standard in assay buffer on the microtitre plate, to give a final
volume of 100 pi in each well. To detect non-specific binding, use 100 pi of assay
buffer as blank. Incubate for 1 h @ 37°C.

6.

Wash as in step 2.

7.

Add 100 pi of anti-ferritin-alkaline phosphatase conjugate diluted in assay buffer.
Incubate for 1 h @ 37"C.

8.

Wash as in step 2.

9.

Pipette 100 pi of a freshly prepared substrate solution (2 mg of /?NPP per ml of
substrate buffer) and incubate at room temperature for 20 min.

10. Read the absorbances of the wells @ 405 nm.
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3.2 Affinity-Column-Mediated Flow-Through ELISA for Ferritin

3.2.1 Preparation of buffers

3.2.1.1 Buffers used in the preparation of the Sepharose gel
•

0.1 mol/1 acetate, pH 4.0, containing 0.5 mol/1 NaCl. Dissolve 1.23 g of NaC2H302,
97.24 ml of C2H4O2, and 29.22 g of NaCl in 800 ml of dH20. Adjust pH with 6
mol/l HCl/NaOH and make up volume to 1 litre with dH20.

• 0.1 mol/l Tris-HCl, pH 8.0, containing 0.5 mol/l NaCl. Dissolve 12.11 g of Tris and
29.22 g of NaCl in 800 ml of dH20. Adjust the pH using 6 mol/l HCl and make up
to 1 litre with dH20.
•

1 mmol/1 HCl. Pipette 32 pi of concentrated HCl into 1 litre of distilled water.

3.2.1.2 Coupling buffer
• 0.1 mol/l bicarbonate, pH 8.5, containing 0.5 mol/l NaCl. Dissolve 8.23 g of
NaHCOs, 0.21 g ofNa2C03, and 29.22 g of NaCl in 800 ml of dH20. Adjust pH
with 6 mol/l HCl/NaOH and make up volume to 1 litre with dH20.

3.2.1.3 Blocking buffer
•

1 mol/l ethanolamine, pH 8.0. Add 60.78 ml of ethanolamine to 800 ml of dH20.
Adjust pH using 6 mol/l HCl and make up to 1 litre.
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3.2.1.4 Carrier buffer
•

50 mmol/1 Tris-HCl, pH 7.4, containing 0.5 mol/1 NaCl, 0.1% (w/v) BSA and
0.035% (v/v) Tween 20. Dissolve 6.06 g of Tris and 29.22 g of NaCl in 800 ml of
dH20 and adjust the pH to 7.4 using 6 mol/1 HCl. Dissolve 1 g of BSA and 350 pi
of Tween 20, and make up the volume to 1 litre using dH20.

2.2.1.5 Substrate buffer
• 0.1 mol/l Tris-HCl, pH 9.8, containing 1.5 mol/1 NaCl. Dissolve 12.11 g of Tris and
87.66 g of NaCl in 800 ml of dH20. Adjust the pH with 6 mol/l HCl and make up to
1 litre with dH20.

3.2.1.6 Regeneration buffer
• 0.1 mol/l glycine, pH 2.1. Dissolve 7.5 g of glycine in 800 ml of dH20. Adjust the
pH with 6 mol/l HCl and make up to 1 litre with dH20.

3.2.1.7 Amplifier substrate buffer
• 50 mmol/1 diethanolamine/HCl, pH 9.5, containing 1 mmol/1 MgCb. Pipette 4.93 ml
of diethanolamine into and dissolve 0.095 g of MgCb in 800 ml of dH20. Adjust pH
to 9.5 using 6 mol/l HCl and make up to 1 litre using dH20.

3.2.1.8 Amplifier buffer
• 20 mmol/1 phosphate buffer, pH 7.2, containing 4% ethanol and 5 mg/ml BSA.
Dissolve 0.68 g of NaH2P04 and 2.03 g of Na2HP04 in 800 ml of dH20. Adjust pH
to 7.2 with 6 mol/l HCl/NaOH. Add 40 ml of ethanol and 5 g of BSA. Make up to 1
litre with dH20
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3.2.2 Coupling anti-ferritin antibody to CNBr-activated Sepharose 4B*

3.2.2.1 Preparation of Sepharose gel
1.

Weigh out the required amount of freeze-dried powder (1 g of powder = 3.5 ml of
gel) and suspend it in 1 mmol/1 HCl.

2.

The swollen gel should be washed for 15 min with 1 mmol/1 HCl on a sintered
glass funnel. The manufacturer recommends the use of approximately 200 ml of 1
mmol/1 HCl per gram of freeze-dried powder, added in several aliquots.

3.2.2.2 Coupling the ligand
1

Dissolve the ligand to be coupled (anti-ferritin antibody) in coupling buffer. Use 5
ml of coupling solution per gram of freeze-dried powder.

2.

Mix the coupling solution containing the antibody with the washed gel in a
stoppered vessel. Rotate the mixture end-over-end for 1 h at room temperature or
overnight at 4°C. A magnetic stirrer should not be used.

3.

Wash away excess ligand with at least five gel volumes of coupling buffer.

4.

To block any remaining reactive groups, transfer the gel to 1 mol/l ethanolamine
buffer, pH 8.0. Let it stand for 2 h.

5

Wash the product first with 0.1 mol/l acetate buffer, pH 4.0, containing 0.5 mol/l
NaCl, and then with 0.1 mol/l Tris-HCl, pH 8.0, containing 0.5 mol/l NaCl.
Repeat the cycle two more times. Use at least five gel volumes for each buffer.

Manufacturer’s instructions.
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3.2.3 Packing the gel into a polystyrene column^
1.

Place the bottom cap on the end of the column.

2.

Place the column in a test tube (16 x 150 mm) and add 3.0 ml of dH20.

3.

Float one of the porous polyethylene discs on top of the liquid within the column.

4.

Depress the disc evenly to the bottom of the column using the insertion rod
supplied with the columns.

5.

Empty the column of water and add a volume of gel slurry required to give a final
volume of 0.5 ml of settled gel.

6.

Allow 30 min for the gel to settle.

7.

Place a second polyethylene disc on top of the liquid within the column and
depress it to just above the settled gel. Leave approximately 1-2 mm of space
between the top of the gel bed and the bottom of the top disc.

8

Wash the inside top part of the column to clean out any gel that may have
remained along the sides during packing.

9.

For storage, keep approximately 2 ml of dH20 over the top disc to prevent drying
out. Place the top cap on the column and store upright at 4°C.

3.2.4 Using the packed column^
1.

To use the column, remove the top cap first. This prevents bubbles being drawn
into the gel. Next, remove the bottom cap and place the column in a suitable
holder, e.g., 16 x 150 mm test tube. Allow the water to drain completely from the
column.

Modification of the manufacturer’s instructions.
Manufacturer’s instructions.
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2. If air bubbles are entrapped in the gel, spin the column first at 1,000 g for 10 min.
This procedure is important, since air bubbles significantly reduce flow rates.

3.2.5 General procedure for the measurement of ferritin
1.

Equilibrate all columns with at least 3 ml of carrier buffer.

2.

Pipette 200 |li1 of standards (ferritin dissolved in carrier buffer) or samples into
separate columns and allow them to pass through under gravity. Add 500 pi of
carrier buffer to each column to wash antigen further into the gel.

3.

Pass 500 pi of the anti-ferritin-alkaline phosphatase conjugate diluted in carrier
buffer through each column.

4.

Wash the excess through using carrier buffer.

5.

Add 500 pi of substrate solution (2 mg of pNPP per ml of substrate buffer) to
each column and incubate at room temperature. The timing of substrate incubation
should be started upon addition of substrate to the first column.

6.

Transfer the columns to clean test tubes (10 x 100 mm) and elute pNP product
using 1 ml of carrier buffer. To ensure that the timing of incubation of substrate
within each column is precise, elution buffer should be added to the batch of
columns in the same sequence as the addition of substrate. Therefore, if one
assumes that the speed of pipetting substrate approximates the speed of pipetting
elution buffer, the time of incubation of substrate should be the same within each
column.

7.

Pipette 100 pi of the eluate in each tube to a microtitre well and read their
absorbances at 405 nm using the Dynatech MR7000.
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4 Results

4 Results

4.1 Conventional Two-Site Sandwich ELISA for Ferritin

4.1.1 Comparison of antibody concentrations for immobilisation to solid phase
a) Standard curves were prepared at various anti-ferritin antibody concentrations:
1.63, 3.25, 6.5, 13, 26 pg/ml. Immobilisation was carried out overnight.
b) Ferritin antigen concentrations: 0, 1.95, 3.9, 7.8, 15.6, 31.25, 62.5, 125, 250, 500,
and 1,000 pg/l.
c) Anti-ferritin-alkaline phosphatase conjugate concentration: 0.098 p-g/ml.
d) Each standard curve was prepared in triplicate.

Table 4.1.1 Comparison of coating antibody concentrations: results
Ferritin concentration (|ig/l)

Mean absorbance at 405 nm (n=3)
Primary antibody concentration (/ug/ml)
1.63

3.25

6.5

13

26

1,000

0.541

0.649

0.751

0.732

0.833

500

0.495

0.632

0.707

0.777

0.907

250

0.535

0.699

0.77

0.794

0.880

125

0.552

0.642

0.707

0.676

0.729

62.5

0.484

0.518

0.548

0.530

0.556

31.25

0.396

0.386

0.393

0.390

0.402

15.6

0.269

0.259

0.278

0.261

0.264

7.8

0.182

0.172

0.180

0.176

0.175

3.9

0.131

0.115

0.119

0.110

0.118

1.95

0.094

0.089

0.099

0.088

0.090

Blank

0.061

0.06

0.061

0.061

0.067

100

Ferritin concentration (^g/1)
26

13

6.5

■

3.25

■

1.63

Figure 4.1.1 Comparison of antibody concentrations for immobilisation to
solid phase.
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4.1.2 Comparison of conjugate antibody concentrations

a) Standard curves were prepared using various anti-ferritin-alkaline phosphatase
conjugate concentrations: 0.049, 0.065, 0.098, 0.196, 0.49 pg/ml.
b) Anti-ferritin antibody concentration used for coating solid phase: 6.5 fig/ml.
Antibody immobilisation was carried out using an overnight incubation.
c) Ferritin antigen concentrations: 0, 1.95, 3.9, 7.8, 15.6, 31.25, 62.5, 125, 250, 500,
and 1,000 |j,g/l.
d) Each standard curve was prepared in triplicate.

Table 4.1.2 Comparison of conjugate antibody concentrations: results
Mean absorbance at 405 nm (n=3)

Ferritin concentration (pg/I)

Conjugate antibody concentration (fig ml)
0.049

0.065

0.098

0.196

0.49

1,000

0.345

0.409

0.546

0.924

2.065

500

0.366

0.415

0.571

0.943

2.196

250

0.396

0.480

0.671

1.067

2.157

125

0.378

0.435

0.614

0.973

1.911

62.5

0.330

0.381

0.500

0.815

1.374

31.25

0.213

0.327

0.419

0.577

0.806

15.6

0.233

0.257

0.311

0.386

0.470

7.8

0.201

0.205

0.228

0.262

0.302

3.9

0.170

0.168

0.179

0.199

0.211

1.95

0.152

0.151

0.157

0.160

0.168

Blank

0.141

0.129

0.129

0.126

0.133
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0.049

•

0.065

■

0.098

■

•

0.196

0.49

■

Figure 4.1.2 Comparison of conjugate antibody concentrations.
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4.1.3 Reduction of the incubation time for the immobilisation of anti-ferritin
antibody to solid phase

a) Two standard curves were prepared using primary antibody coated at 4”C overnight
(0/N) and at 4T for 2 h.
b) Anti-ferritin antibody concentration; 6.5 pg/ml.
c) Ferritin antigen concentrations: 0, 1.95, 3.9, 7.8, 15.6, 31.25, 62.5, 125, 250, 500,
and 1,000 fj.g/1.
d) Concentration of conjugate antibody: 0.196 pg/ml.
e) Each standard curve was prepared in triplicate.

Table 4.1.3 Reduction of incubation time for coating antibody to solid phase: results
Ferritin concentration (pg/l)

Mean absorbance at 405 nm (n=3)

Incubation conditions
4T O/N

4T 2h

1,000

1.195

1.213

500

1.207

1.253

250

1.212

1.31

125

1.041

1.057

62.5

0.774

0.777

31.25

0.527

0.503

15.6

0.339

0.307

7.8

0.200

0.184

3.9

0.129

0.120

1.95

0.095

0.086

Blank

0.057

0.057
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■ 4 degrees 0/N

• 4 degrees 2 h

Figure 4.1,3 Reduction of the incubation time for the immobilisation of antiferritin antibody to solid phase.
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4.1.4 Precision and limit of detection (L.O.D.)

a) Each ferritin standard and blank (0.975-500 }ag/l) was analysed in replicates of
twelve.
b) Anti-ferritin antibody was coated for 2 h at 4°C using a concentration of 6.5 pg/ml.
c) Anti-ferritin-alkaline phosphatase conjugate concentration: 0.196 |ag/ml.
d) The limit of detection was estimated from the standard curve as the concentration of
ferritin giving an absorbance corresponding to the absorbance of the blank plus
three standard deviations.

Table 4.1.4 Determination of precision and detection limit: results
Cone. (|ig/l)

Mean abs405 nm

S.D. (A.U.)

C.V. (%)

500

1.203

0.036

2.99

250

1.239

0.037

2.99

125

0.974

0.042

4.31

62.5

0.707

0.029

4.10

31.25

0.487

0.036

7.39

15.6

0.272

0.015

5.51

7.8

0.168

0.009

5.36

3.9

0.125

0.011

8.80

1.95

0.104

0.006

5.77

0.975

0.091

0.007

7.69

Blank

0.081

0.007

8.64

-16
From the graph, the L.O.D. = <1.95 pg/1 or 4.33 x 10'^^ mol/l (4.33 x lO'""
mol)
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4.2 Development of the Affinity-Column-Mediated ELISA

4.2.1 Preparation of a standard curve
a) Freshly prepared columns were used. Coupling antibody concentration: 500 pg per
gram of gel.
b) Ferritin antigen concentrations: 0, 31.25, 62.5, 125, 250, and 500 pg/1.
c) Conjugate concentration: 0.98 pg/ml.
d) Volume of carrier buffer used to remove residual label: 5 ml.
e) Substrate incubation time: 30 min.

Table 4.2.1 Standard curve: results
Ferritin concentration (pg/1)

Absorbance at 405 nm

500

1.550

250

0.961

125

0.580

62.5

0.348

31.25

0.220

0

0.106

10

Figure 4.2.1 Column ELISA : standard curve.
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4.2.2 Comparison of coupling antibody concentrations

a) Standard

curves

were

prepared

using

three

different

coupling

antibody

concentrations: 1,000 pg/g, 500 pg/g, and 250 pg/g.
b) Freshly prepared columns were used.
c) Ferritin antigen concentrations: 0, 3 1.25, 62.5, 125, 250, and 500 pg/1.
d) Conjugate concentration: 0.98 pg/ml.
e) Volume of carrier buffer used to remove residual label: 5 ml.
f) Substrate incubation time: 30 min.

Table 4.2.2 Comparison of coupling antibody concentrations: results
Absorbance at 405 nm

Ferritin concentration (pg/1)

Coupling antibody concentration (tig g)
250

500

1,000

500

1.202

1.507

1.520

250

0.706

0.926

0.957

125

0.417

0.518

0.559

62.5

0.273

0.335

0.345

31.25

0.167

0.211

0.227

0

0.082

0.103

0.074

112

■250

■500

1,000

Figure 4.2,2 Comparison of coupling antibody concentrations.
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4.2.3 Comparison of conjugate antibody concentrations

a) Standard

curves were

prepared

using three

different

conjugate

antibody

concentrations: 1.96, 0,98, and 0.49 tig/ml.
b) Freshly prepared columns were used. Coupling antibody concentration: 500 pg/g.
c) Ferritin antigen concentrations: 0, 31.25, 62.5, 125, 250, and 500 pg/1.
d) Volume of carrier buffer used to remove residual label: 5 ml.
e) Substrate incubation time: 15 min.

Table 4.2.3 Comparison of conjugate antibody concentrations: results
Absorbance at 405 nm

Ferritin concentration (pg/1)

Conjugate antibody concentration’ (mrnl)
0.49

0.98

1.96

500

0,408

0.789

1.443

250

0.269

0.461

0.811

125

0.192

0.311

0.523

62.5

0.149

0.190

0.300

31.25

0.110

0.129

0.174

0

0.082

0.083

0.085

114

•

0.49

0.98

■

1.96

Figure 4.2.3 Comparison of conjugate antibody concentrations.
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4.2.4 Reduction of buffer volume used for removal of excess conjugate antibody

a) Various volumes of carrier buffer were compared for their ability to remove excess
conjugate antibody from the column.
b) To assess the efficacy of each buffer volume, conjugate antibody was added to a
column, the column was washed, and pNPP substrate was added. Therefore, any
absorbance reading would represent conjugate antibody non-specifically bound.
c) Freshly prepared columns were used. Coupling antibody concentration: 500 p-g/g.
d) Conjugate concentration; 1.96 pg/ml.
e) Substrate incubation time: 30 min.

Table 4.2.4 Reduction of washing buffer volume; results
Volume of buffer (ml)

Absorbance at 405 nm

0.5

0.229

1

0.133

2

0.107

3

0.098

5

0.087

1 + 1

0.078

1 +2

0.080

1+2 + 2

0.089
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4.2.5 Efficacy of regeneration in removing bound antigen and label

a) Three standard concentrations, 1,050, 2,100, and 4,200 fig/l, plus a blank were
assayed in triplicate.
b) Freshly prepared columns were used. Coupling antibody concentration; 500 |ag/g.
c) Conjugate concentration: 1.96 |ig/ml.
d) Washing volume for removal of excess conjugate: 1 + 1 ml.
e) Substrate incubation for 10 min.
f) To regenerate the columns, 1 ml of regeneration buffer was introduced into each
column, followed by 2 ml of carrier buffer. This cycle was repeated two more times.
g) After regeneration, all columns were used to assay blanks using the conjugate
concentration of 1.96 |J,g/ml, a washing volume of 1 + 1 ml, and a substrate
incubation time of 30 min.

Table 4.2.5 Efficacy of regeneration; results
Absorbance at 405 nm

Ferritin concentration (|J.g/i)
1

2

3

Mean

S.D.

4,200

>3.00

>3.00

>3.00

-

-

2,100

2.690

2.690

2.389

2.590

0.174

1,050

1.521

1.510

1.401

1.477

0.066

0

0.081

0.082

0.088

0.084

0.004

Absorbance at 405 nm post regeneration
1

2

3

Mean

S.D.

4,200

0.172

0.166

0.169

0.169

0.003

2,100

0.135

0.142

0.130

0.136

0.006

1,050

0.071

0.071

0.073

0.072

0.001

0

0.081

0.079

0.079

0.080

0.001
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4.3 Validation of the Affinity-Column-Mediated ELISA

4.3.1 Final assay conditions - Supplementary to general protocol (Section 3.2.5)
a) Coupling antibody concentration; 500 pg/g.
b) Conjugate concentration; 1.96 pg/ml.
c) Washing volume for removal of excess conjugate; 1 + 1 ml.
d) Substrate incubation; 30 min.
e) Regeneration using three cycles of 1 ml of regeneration buffer, followed by 2 ml of
carrier buffer.

4.3.2 Determination of the limit of detection and working range
a) Ferritin standards ranging from 4.1-525 pg/1 and a blank were assayed in replicates
of five.
b) The limit of detection was estimated from the standard curve as the concentration of
ferritin giving an absorbance corresponding to the absorbance of the blank plus
three standard deviations.
c) The working range was derived from the precision profile.
d) To assess the effect of the regeneration process on the detection limit and on the
working range, the assay was performed a further nine times using the same
columns.
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Table 4.3.1 Determination of the limit of detection and working range: results run 1
C.V. (%)
Ferritin concentration tus/ll Mean abs405nm (n= 5) S.D. lA.U.)
2.320
0.016
0.069
525
1.450
0.020
262.5
1.379
0.926
0.031
3.348
131.2
0.543
0.004
65.6
0.737
0.349
32.8
0.010
2.875
16.4
0.221
0.004
1.810
0.166
0.002
8.2
1.205
0.130
4.1
0.003
2.308
0
0.095
0.002
2.105
From the graph, the L.O.D. = 0.7 pg/l or 1.55 X 10''^ mol/l(3.ll X 10'"* mol)

Figure 4.3.1 Standard curve: run 1.
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Table 4.3.2 Determination of the limit of detection and working range; results run 2
Ferritin concentration tue/I) Mean abs40fsnni (n= 5) S.D. (A.U.)
C.V. (%)
525
2.964
0.033
1.113
262.5
2.038
0.051
2.502
131.2
1.244
0.029
2.331
65.6
0.766
0.015
1.958
32.8
0.474
0.012
2.532
16.4
0.296
0.010
3.378
8.2
0.200
0.002
1.000
4.1
0,152
0.002
1.316
0
0.099
0.004
4.040
From the graph, the L.O.D. = 1.0 ng/l or 2,22 X 10''^ mol/1 (4.44 X lO'*^ mol)

Figure 4.3.3 Standard curve: run 2.
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Table 4.3.3 Determination of the limit of detection and working range: results run 3
C.V. (%)
Ferritin concentration fu2/l) Mean abs405inm (n= 5) S.D. (A.U.)
2.101
0.038
525
1.809
1.324
0.038
262.5
2.870
0.752
0.023
131.2
3.059
0.466
65.6
0.003
0.644
32.8
0.283
0.002
0.707
16.4
0.190
0.005
2.632
0.140
8.2
0.001
0.714
0.119
4.1
0.001
0.840
0
0.096
0.003
3.125
From the graph, the L.O.D. = 1.6pg/l or 3.56 X 10'^^ mol/l(7.11 X 10'“^ mol)

Figure 4.3.5 Standard curve: run 3.
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Table 4.3.4 Determination of the limit of detection and working range: results run 4
Ferritin concentration tue/1)

Mean abs405nm (n=5)

C.V. (%)

0.030
1.445
0.045
3.641
0.025
3.429
0.008
1.826
0.005
1.818
0.003
1.639
0.001
0.699
0.002
1.681
0.001
1.053
From the graph, the L.O.D. = 0.6 |ig/l or 1.33 X 10'^^ mol/l (2.67 X 10'^^ mol)
525
262.5
131.2
65 6
32.8
16.4
8.2
4.1
0

2.076
1.236
0.729
0.438
0.275
0.183
0.143
0.119
0.095

S.D. (A.U.)

Figure 4.3.7 Standard curve: run 4.
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Table 4.3.5 Determination of the limit of detection and working range; results run 5
C.V. (%)
Ferritin concentration (ng/1) Mean abs405nm (n= 5) S.D. (A.U.)
2.307
0.065
525
2.818
1.417
262.5
0.075
5.293
0.761
131.2
0.015
1.971
65.6
0.464
0.015
3.233
32.8
0.232
0.006
2.586
16.4
0.169
0.004
2.367
8.2
0.133
0.002
1.504
4.1
0.115
0.001
0.870
0
0.096
0.003
3.125
From the graph, the L.O.D. = 1.9pg/l or 4.22 X 10'*^ mol/l (8.44 X 10'^^ mol)

Figure 4.3.9 Standard cun^e: run 5.
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Table 4.3.7 Determination of the limit of detection and working range; results run 6
Ferritin concentration (|ig/l) Mean abS405 nm (n=5) S.D. (A.U.)
525
2.489
0.058
262.5
1.547
0.042
131.2
0.919
0.048
65.6
0.536
0.009
0.329
32.8
0.009
16.4
0.212
0.003
8.2
0.155
0.003
4.1
0.130
0.005
0
0.102
0.004
From the graph, the L.O.D. = 1.8 pg/1 or 4 x 10’’^ mol/l (8 x 10'^^ mol)

Figure 4.3.11 Standard curve: run 6.
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Table 4.3.8 Determination of the limit of detection and working range: results run 7
Ferritin concentration (ue/l) Mean abs405nm (n= 5) S.D. (A.U.)
C.V. (Vo)
525
2.894
0.039
1.348
262.5
1.967
0.029
1.474
131.2
1.183
0.038
3.212
65,6
0.685
0.011
1.606
32.8
0.416
0.007
1.683
16.4
0.256
0.007
2.734
8.2
0.179
0.004
2.235
4.1
0.142
0.004
2.817
0
0.102
0.002
1.961
From the graph, the L.O.D. = 0.6pg/l or 1.33x10'’^ mol/l (2.67 X 10’^^ mol)

Figure 4.3.13 Standard curx’e: rim 7.
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Table 4.3.8 Determination of the limit of detection and working range: results run 8
C.V. (%)
Ferritin concentration (ue/1) Mean abs405nm (n=5) S.D. (A.U.)
2.489
0.111
525
4.460
1.552
0.080
262.5
5.155
131.2
0.833
0.011
1.321
65.6
0.483
0.007
1.449
32.8
0.301
0.003
0.997
16.4
0.198
0.003
1.515
8.2
0.147
0.002
1.361
4.1
0.119
0.002
1.681
0
0.092
0.002
2.174
-16
From the graph, the L.O.D = 1.0 pg/l or 2.22 x 10'^^ mol/l (4.44 x lO'*'’
mol)

Figure 4.3.15 Standard curve: run 8.

133

C.V. (%)

ex)

n.

m

—

b

00

s:
">*

%■
Ci,

s:

•2
•3
'o

as

VO

>*
s

i?

Table 4.3.9 Determination of the limit of detection and working range: results run 9
C.V. (%)
Ferritin concentration tue/1) Mean abs405nm (n=5) S.D. (A.U.)
525
2.523
0.043
1.704
262.5
1.496
0.031
2.072
0.885
0.005
131 2
0.565
0.519
65.6
0.014
2.697
32.8
0.291
0.001
0.344
16.4
0.200
0.003
1.500
8.2
0.157
0.002
1.274
4.1
0.126
0.003
2.381
0
0.104
0.002
1.923
-16
From the graph, the L.O.D. = 1.2 pg/1 or 2.67 x 10’’^ mol/l (5.33 x lO'*'’
mol)

Figure 4.3.17 Standard curve: run 9.
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Table 4.3.10 Determination of the limit of detection and working range: results run 10
Ferritin concentration (ue/1) Mean abs405nm (n=5) S.D. (A.U.)
C.V. (%)
525
2.233
0.095
4.254
262.5
1.321
0.031
2.347
131.2
0.804
0.032
3.980
65.6
0.469
0.020
4.264
32.8
0.272
0.004
1.471
16.4
0.182
0.003
1.648
8.2
0.144
0.004
2.778
4.1
0.123
0.004
3.252
0
0.094
0.003
3.191
From the graph, the L.O.D. = 1.3 pg/l or 2.89 x 10'‘^mol/l(5.78x 10''^ mol)

Figure 4.3.19 Standard curve: run 10.
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4.3.3 Assessment of within-run precision

a) Three serum pools (A, B, & C), representing different levels of the working range,
were assayed in replicates of ten using freshly prepared columns.
b) Standard ferritin concentrations: 0, 8.2, 16.4, 32.8, 65.6, 131.25, 262.5, and 525

Table 4.3.11 Within-run precision: standard curve results
Ferritin concentration (|ig/I)

Absorbance at 405 nm

525

2.761

262.5

1.606

131.25

1.002

65.6

0.601

32.8

0.362

16.4

0.236

8.2

0.148

0

0.095

139

10

100

Ferritin concentration (fxg/l)

Figure 4.3.21 Within-run precision: standard curve.
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4.3.4 Assessment of between-run precision

a) The three serum pools (A, B, & C) were assayed singly for a further nine assays
using the same columns used in the assessment of within-run precision.
b) Standard ferritin concentrations: 0, 5.5, 11, 22, 43.75, 87.5, 175, 350, and 525 pg/l.
c) The mean concentrations from the assessment of within-run precision were also
used in the calculations of between-run precision.

Table 4.3.13 Between-run precision: results for serum pools A, B, and C
Assay

Measured concentration (p.g/1)

Pool A

Pools

Pool C

Within-run

8.98

90.2

350.6

1

11

100

342

2

9.5

82

306

3

10

94

320

4

9.5

86

306

5

11

86

334

6

10.5

96

316

7

13

84

315

8

10.5

86

302

9

11

78

279

10.50

88.22

317.06

S.D. (ng/1)

1.13

6.77

21.00

C.V. (%)

10.76

7.67

6.62

Mean (|ig/I)
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4.3.5 Analytical recovery

a) Human serum devoid of ferritin was spiked with known amounts of ferritin standard
and analysed by the present assay on columns regenerated once.
b) Standard ferritin concentrations: 0, 4.1, 8.2, 16.4, 32.8, 65.6, 131.25, 262.5, and
525 pg/1.

Table 4.3.14 Analytical recovery: standard curve results
Ferritin concentration (|ig/l)

Absorbance at 405 nm

525

2.879

262.5

1.837

131.25

1.076

65.6

0.597

32.8

0.348

16.4

0.217

8.2

0.142

4.1

0.109

0

0.079

Table 4.3.15 Analytical recovery: results
Absorbance at 405 nm

Ferritin concentration (|ig/l)

Recovery (%)

Observed

Expected

2.506

437

480

91

1.913

278

267

104.1

1.402

188

185

101.6

0.748

87

93

94.1

0.652

73

67

108.9

0.435

45

47

97.3

0.261

22

20

110

0.119

5.4

5

108

143

Figure 4.3.22 Recovery study: standard curve.
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4.3.6 Linearity

a) Three human serum samples (A, B, & C) with high ferritin concentrations were
diluted in the standard matrix, i.e., carrier buffer, and were analysed using the
present assay.
b) Standard ferritin concentrations; 0, 4.1, 8.2, 16.4, 32.8, 65.6, 131.25, 262.5, and
525 pg/1.
c) Freshly prepared columns were used.

Table 4.3.16 Linearity study: standard curve results
Ferritin concentration (p.g/1)

Absorbance at 405 nm

525

2.948

262.5

1.664

131.25

0.963

65.6

0.533

32.8

0.314

16.4

0.204

8.2

0.139

4.1

0.111

0

0.089
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Figure 4.3.23 Linearity study: standard curve.
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Volume of sample (pi)
♦

B ------ C

Figure 4.3.24 Linearity of column ELISA.
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Standard

Figure 4.3.25 Parallelism of column ELISA.
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4.3.7 Correlation study

a) Thirty serum samples were measured using the present assay and the results were
compared to those obtained using the chemiluminescence immunoassay on the
ACS: 180 (Ciba Corning Diagnostics, Medfield, MA, USA).
b) Samples with high ferritin values were diluted 1/2.
c) The columns were previously used seven times.
d) Standard ferritin concentrations: 0, 8.2, 16.4, 32.8, 65.6, 131.25, 262 5, and 525

4g/!

Table 4.3.18 Correlation study: standard curve results
Ferritin concentration (|.ig/l)

Absorbance at 405 nm

525

1.979

262.5

1.150

131.25

0.643

65.6

0.366

32.8

0.230

16.4

0.154

8.2

0.115

0

0.080

50

Figure 4.3.26 Correlation study: standard curve.
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Table 4.3.19 Correlation study; sample results
Sample no.

Sample volume (pi)

Absorbance405 nm

Cone, (pg/1)
Observed Expected

1

200

0.172

20

23

2

200

0.454

85

69

3

200

0.176

21

16

4

100(1/2)

1.185

540

449

5

200

0.281

44

41

6

200

0.548

107

91

7

200

0.119

9

9

8

200

0.170

17

19

9

200

1.680

415

418

10

200

0.507

98

89

11

200

0.535

104

84

12

100(1/2)

1.250

580

539

13

100(1/2)

1.526

730

641

14

200

0.224

31

31

15

200

0.172

20

53

16

200

0.244

35

34

17

200

0.122

9

11

18

200

0.428

79

71

19

200

0.125

10

8

20

100(1/2)

1.364

640

624

21

200

1.106

245

254

22

200

1.202

270

284

23

200

0.708

145

130

24

200

0.390

70

64

25

200

0.253

38

40

26

200

0.284

45

41

27

200

0.344

59

60

28

200

0.906

198

145

29

200

0.276

44

45

30

200

0.416

75

69
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4.3.8 Amplification of signal

a) In an attempt to increase the sensitivity of the assay, a standard curve was prepared
using a modification of the amplification system for alkaline phosphatase detection
(Self, 1985; Moss et al., 1985; Stanley et al., 1985, Johannsson et al., 1986; Dhahir
etal., 1992)
b) Once excess conjugate antibody was removed, 500 pi of substrate (0.2 mmol
PNADP per litre of amplifier substrate buffer) was added to each column and the
columns were incubated at room temperature for 20 min.
c) The columns were transferred to clean test tubes (10 x 100 mm) and the NAD
product was eluted using 1 ml of carrier buffer.
d) Eluate (50 pi) from each column was pipetted into a well on a microtitre plate
e) Subsequently,

50 pi of amplifier (2.5

mmol INT,

675 units of alcohol

dehydrogenase, and 1,620 units of diaphorase per litre of amplifier buffer) was
added to each well and the plate was incubated for 5 min at room temperature.
f) The reaction was stopped using 50 pi of 2 mol/l H2SO4 and the absorbance of each
well was read at 490 nm.
g) Standard ferritin concentrations: 0, 0.5, 1, 2, 4.1, 8.2, 16.4, 32.8, 65.6, 131.25,
262.5, and 525 pg/1.
h) The assay volume used was 50 pi.
i) The columns had been previously used thirteen times.
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Table 4.3.20 Amplification of signal; results
Absorbance at 490 nm
2.248
1.964
1.372
0.929
0.549
0.351
0.254
0.216
0.168
0.145
0.136
0.124

Ferritin concentration (pg/l)
525
262.5
131.25
65.6
32.8
16.4
8.2
4.1
2
1
0.5
0
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Figure 4.3.28 Amplification of enzyme label: standard curve.
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5 Discussion

5 Discussion

Immunoassays are renowned for their specificity, sensitivity, and reliability (Ekins,
1985). However, probably their greatest limiting factor is the requirement for
prolonged incubations, resulting in assays taking several hours to complete. With this
limitation in mind, the objective of this work was to develop and validate a flow
through two-site sandwich ELISA, which eliminates the requirement for lengthy
incubations of antigen and antibody, while still maintaining the sensitivity and reliability
associated with conventional immunoassay. System simplicity and reusability were also
of consideration.
To ensure that the antibodies used could recognise their specific antigen, a
conventional two-site sandwich ELISA was developed using 96-well microtitre plates
as solid phase. Anti-ferritin antibody immobilised onto the walls of the plastic wells
was used to capture ferritin antigen, which was then detected using the anti-ferritinalkaline phosphatase conjugate. Subsequently, bound conjugate was detected using pnitrophenyl phosphate as substrate. Therefore, the assay was equivalent to assays
belonging to Group 4 of Gosling’s classification (Gosling, 1990). This development
was not intended to constitute a full or comprehensive optimisation, but it was merely
intended to provide proof of antigen recognition by both antibodies and, thus, their
suitability for use in the column-based immunoassay.
The starting point with any solid-phase immunoassay is the determination of the
optimum conditions for biomolecule immobilisation. Probably, the most convenient
and indeed the most popular medium is the plastic microtitre plate. For example, in
1990 plastic microtitre plate technology could be found in 70% of all new solid-phase
157

immunoassays Their popularity is most probably due to the large batches of assays
that can be carried out using automated instruments purposefully designed for
microtitre plates, e g., pipettors, washers, and readers. Therefore, for the purposes of
this study, it was decided to use polystyrene microtitre plates supplied by Nunc as solid
phase.
As discussed earlier (Section 1.8), biomolecules may be bound to surfaces either
through covalent attachment or via passive adsorption. By far the easiest method to
coat the microtitre plate is to do so directly by passive adsorption to the surface of the
plastic (Kemeny, 1992). Since a large surface area is needed to immobilise
biomolecules in this manner, the binding capacity of polystyrene is approximately 100200 ng IgG/cm^ (Gibbs 1995a). However, it has been shown that irradiation of the
polystyrene surface can increase the binding capacity to between 400 and 500 ng
IgG/cm^ (Gibbs 1995a). According to Gibbs (1995a), the mechanism of immobilisation
in this case is by passive adsorption through hydrophobic and ionic interactions. Gibbs
(1995a) also states that the latter require a smaller portion of the molecule be in
contact with the surface, thus increasing the binding capacity. A negative aspect of
passive adsorption is that <3.0% of the binding sites of monoclonal antibodies and
approximately 5-10% of those of polyclonal antibodies are capable of binding antigen
(Butler et al., 1992). However, in the interests of simplicity, passive adsorption was
used in this study to coat the anti-ferritin antibody to the solid phase.
According to Kemeny (1992), the optimum concentration for coating antibodies to
plastic microtitre plates by passive adsorption typically lies between 1 and 10 pg/ml. In
the literature, concentrations between 0.4 and 10 pg/ml have been quoted for
adsorbing antibody to plastic microtitre plates and tubes (Krachmalnicoff et al., 1990;
Papoian et al., 1992; Noe et al., 1992; Aubin et al., 1997; Dhahir et al., 1992; Munro
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and Stabenfeldt, 1984). At higher concentrations, molecules tend to bind loosely,
forming multiple layers, which are unstable and peel off during the assay. A
comparison of anti-ferritin antibody concentrations in this study (Section 4.1.1)
revealed that there was little difference between antibody concentrations of 1.63 to 26
tig/ml m binding ferritin antigen up to approximately 30 pg/1. It was therefore evident
from the results that an increase in antibody concentration beyond 1.6 pg/ml would not
improve on the lower limit of detection, but it would permit the assay of higher
concentrations of ferritin with greater sensitivity, and without an associated increase in
background noise. In fact, the results showed that antibody binding was at its greatest
when a concentration of 26 pg/ml was used, a finding which may be considered
somewhat contradictory to the findings of previous studies (e g. Aubin et al., 1997).
Such contradiction may be due to a larger binding capacity of the Nunc Maxisorp
plates used as compared to conventional systems. Therefore, higher antibody
concentrations are required to obtain maximum binding and a confluent monolayer.
Alternatively, the nature of the coating buffer used (0.05 mol/1 carbonate, pH 9 6) may
have influenced the affinity of the antibodies for the plastic surface. Further study may
have shown different pH coating buffers to be more effective, e.g., phosphate, pH 7.4
or acetate, pH 5.0. In any case, for further work it was decided to immobilise using 6.5
pg of antibody dissolved in 1 ml of 0.05 mol/l carbonate buffer, pH 9.6, simply because
it gave a satisfactory curve and was more economical to use than a concentration of 26
pg/ml.
Generally, signals obtained in two-site sandwich immunoassay increase in proportion
to increasing labelled antibody concentration, until a point is reached at which further
increases in label serve only to increase non-specific binding. Antibody in this situation
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is in excess. To determine the optimum anti-ferritin-alkaline phosphatase conjugate
concentration for use in this system, a series of standard curves were prepared using
various concentrations of conjugate antibody (Section 4.1.2). As expected, the
steepness of the curves increased with increasing label concentration and without an
undesirable increase in the background signal. Best results were obtained using a
concentration of 0.49 p-g/ml, however, further increases in concentration may have
proven advantageous. In any case, it was decided to use the sub-optimal concentration
of 0 196 pg/ml for further study.
For the previous studies, antibody immobilisation was carried out using an overnight
incubation at 4°C. Since such a procedure had an obvious disadvantage, it was
attempted to reduce the time of incubation from overnight to 2 h. The time taken to
coat a microtitre plate not only depends on the concentration of coating solution, but
also on the temperature at which it is carried out (Kemeny, 1992). Generally, with
increasing temperature the time of incubation can be reduced, however, it has been
shown that 90% of maximum binding occurs with 2-6 h, even at 4°C (Pesce et al.,
1977). Results presented here (Section 4.1.3) appear to be in agreement with this
finding, since a reduction of the incubation time from overnight to 2 h produced
standard curves which differed only slightly.
Of importance also are the incubation conditions used. To achieve maximum signal
sizes and to minimise drifts in results, it is usual to incubate for sufficient time to allow
reactions to achieve or approach equilibrium (Micallef and Ahsan, 1994). Generally,
the higher the incubation temperature, the shorter the times required. In addition,
antigen-antibody reactions normally take place at between pH 6.0 and 9.0 (Kemeny,
1992), so it obviously important to use an incubation/assay buffer within this pH range.
Therefore, for this study, incubation of antigen and conjugate antibody were carried
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separately in a 0.05 mol/1 phosphate buffered saline, pH 12, for 1 h at 37°C. No
attempt was made to determine the times required to achieve maximal binding, since it
was assumed that all reactions were close to equilibrium under such incubation
conditions. Moreover, for most antigens and antibodies near maximal binding occurs
within 2 h (Kemeny, 1992).
The final

assay

showed acceptable within-run precision for standards with

concentrations ranging from 0.975 to 500 pg/l and gave a detection limit of 1.95 pg/l,
equivalent to 4.33 x 10’^^ mol/l or 8.67 x 10’’^ mol per 100 p,! assay volume. However,
this sensitivity was achieved using standards prepared in buffer and would likely be
higher if real (serum) samples were used. Although the system was far from fully
optimised and lacked a complete validation study, it demonstrated the suitability of the
antibody pair for use in the column-mediated ELISA, together with the potential
sensitivity attainable
Column-based flow-through immunoassay has the distinct advantage over conventional
immunoassay systems in that it does not necessitate prolonged incubations of antibody
and antigen in order to achieve binding (de Alwis and Wilson, 1985; Lejeune et al.,
1990; Hage and Kao, 1991; Freytag et al., 1984; Janis and Regnier, 1989; Cassidy et
al., 1992; Nilsson et al., 1994; Kronkvist et al., 1997). Since the nature of the
chromatographic process ensures a rapid contact between agonist (in mobile phase)
and the solid-phase ligand in excess, with minimal reliance on diffusion, the reaction
rate between macromolecules is actually improved (Lejeune et al., 1990). In addition,
mathematical models have shown that agonist binding by a sufficient excess of solidphase ligand can reach 100% irrespective of the agonist concentration or ligand affinity
(Lejeune et al., 1990).
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With these benefits in mind, it was attempted to apply the principles of the
conventional two-site sandwich immunoassay to a flow-through format using columns
loaded with a sufficient excess of anti-ferritin antibody. Theoretically, such an
immunoreactor would be used to immobilise ferritin antigen passing through the
column in the mobile phase. Any bound ferritin would subsequently be detected using a
mobile-phase conjugate antibody, followed by /?NPP substrate to quantitate the bound
label. However, the final addition would have to be accompanied by an incubation
period so that pNP product may be allowed to form within the column. Once the
product has formed, it would have to be eluted from the column before absorbance
readings could be taken.
To obtain a sufficient excess of ligand (antibody) within the column, one needs to
select a coupling medium with a high binding capacity. For this purpose, it was decided
to use CNBr-activated Sepharose 4B Indeed Sepharose has several characteristics
which made it attractive for use in this setting. Firstly, it has a high binding capacity,
enabling coupling of up to 60 mg of a-chymotrypsin/ml of drained gel (CNBractivated Sepharose 4B Instructions, Pharmacia-Biotech, Uppsala, Sweden)

In

addition, the coupling procedure is very simple and safe, requires no specialised
equipment, and can be completed in a matter of hours. The gel is stable within a pH
range of 2-11

(CNBr-activated Sepharose 4B Instructions, Pharmacia-Biotech,

Uppsala, Sweden), thus permitting regeneration of the solid phase using a low pH
elution. In addition, Sepharose has a low non-specific binding (Nilsson et al., 1994).
Of consideration also was the type of column used. To keep the assay on a small scale,
disposable polystyrene columns capable of holding gel volumes of between 0.5 and 2
ml were used. When packed as directed (Figure 5.1), the columns have a unique stopflow action. Aqueous solution applied to a column will automatically stop at the disc
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positioned above the gel when the liquid level reaches it, so the column gel will not dry
out if left unattended. Also, the nature of the system ensures that the quantity of
solution applied to the column will always be equal to the amount of eluate. The
volume of gel decided to pack the columns was the minimum permitted, i.e., 0.5 ml.
Following the design of the column, the general assay protocol was formulated
(Section 3.2.5). For the preparation of the standards and conjugate antibody, it was
decided to use a 50 mmol/1 Tris-HCl buffer, pH 7.4, containing 0.5 mol/l NaCl
(Nilsson et al., 1994). To make the standards resemble serum samples more closely
and to prevent potential binding of labelled antibody to the support, BSA and Tween
20 were also added to the buffer at concentrations of 0.1% (w/v) and 0.035% (v/v),
respectively. This buffer was also chosen for all washing steps. As was the case for the
conventional ferritin immunoassay, a 0.1 mol/l Tris-HCl buffer, pH 9.8, containing 1.5
mol/l NaCl (Ternynck and Avrameas, 1990), was chosen for the incubation of the
/^NPP substrate within the column, since its pKa of 8.1 enables Tris to act as an
excellent buffer for alkaline phosphatase (Tijssen, 1993). In addition, it was decided to
carry out the incubation step at room temperature using a concentration of 2 mg/ml,
since /?NPP is more prone to spontaneous hydrolysis at higher temperatures (Tijssen,
1993) and at higher concentrations.
From the outset, the volumes to be used for sample, conjugate antibody, and substrate
were set at 200 |il, 500 |.d, and 500 pi, respectively. Ideally, to permit the measurement
of low antigen concentrations one should use large volumes of sample, however, when
dealing with serum or plasma there are obvious restrictions. A volume of 200 pi was
deemed an acceptable volume to use. For conjugate antibody, volume seemed less
important, since one can adjust the amount of antibody to suit. Finally, a volume of
500 pi was chosen for the addition of substrate so that it could penetrate the entire
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volume of the gel (0.5 ml). It appeared that little was to be gained by using larger
volumes.
Top cap —►

•Gel

;cs
Polyethylene discs

X
-Bottom cap

Figure 5.1 Polystyrene column packed with gel.

To test the general assay protocol, a standard curve was prepared (Section 4.2.1) using
a coupling concentration of 500 p-g/g, together with a conjugate concentration of 0.98
pg/ml and a substrate incubation time of 30 min. The standard curve obtained was
satisfactory and non-specific binding was negligible when using a buffer volume of 5 ml
to remove residual label.
Pharmacia-Biotech recommends that approximately 5-10 mg of protein be used for
coupling to 1 ml of gel, equivalent to 17.5-35 mg per gram of freeze-dried powder
(since 1 g yields about 3.5 ml of gel). However, this seemed excessive for the purposes
of this assay. To investigate if a coupling concentration of 500 pg/g was achieving
maximal binding of antigen or if lower amounts of antibody could be used without
affecting the signals obtained, standard curves were prepared on columns containing
approximately 140 pg (1,000 pg/g), 70 pg (500 pg/g), and 35 pg (250 pg/g) of
antibody (Section 4.2.2). The results demonstrated that a coupling concentration of
500 pg/g was indeed sub-optimal in that higher concentrations gave better signals
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without an associated increase in background. However, it would be hard to justify
choosing a coupling concentration of 1,000 pg/g over a concentration of 500 pg/g on
economic grounds, since only a slight increase in signals was obtained for a 100%
increase in antibody.
While the chromatographic process gives very efficient binding of antigen rapidly by an
excess of solid-phase antibody, the second step (addition of conjugate antibody) is run
with a lack of stationary phase excess, since the stationary phase level is controlled by
bound antigen (Lejeune et al., 1990). According to Lejeune et al. (1990), antigen
binding by labelled antibody in column formats is not as efficient as binding by label in
conventional systems, even when a significant excess of antibody is added in several
additions. In fact, this procedure only served to increase non-specific binding in their
assay, leading to a decreased signal-to-noise ratio and lower sensitivity. For this assay,
conjugate antibody concentrations of 0.49 and 1.96 pg/ml were compared to the
concentration of 0.98 pg/ml used initially (Section 4.2.3). As expected, increasing the
concentration beyond 0.98 pg/ml produced higher signals, fortunately, without an
associated increase in non-specific binding. Presumably, higher concentrations of label
would produce even better signals, but economy and the risk of increased background
noise eliminated their use. However, the latter aspect would be of a lesser concern,
since the increased amount of residual label could be potentially be removed using
larger volumes of carrier buffer during the washing step. For further assays a
concentration of 1.96 pg/ml was used.
In addition, as part of assay development, an attempt was made to lower the volume of
buffer used previously to remove excess antibody label in earlier assays (Section 4.2.4).
This aspect of the procedure was of particular interest, since 5 ml of buffer passed
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through the columns quite slowly, thus limiting the overall speed of the assay. The
results showed that a 2 ml volume of buffer, added in two 1 ml washes was sufficient
to remove any excess label.
Up to this point in assay development, all studies were performed using freshly
prepared columns. However, the use of fresh columns for each assay proved
expensive, since approximately 70 pg of antibody was used per column. The columns,
however, were reusable. In order to permit the reuse of packed columns after assays, it
was proposed to treat the columns with three cycles of 1 ml of 0.1 mol/l glycine buffer,
pH 2.1, followed by 2 ml of carrier buffer. Having tested the efficiency of such a
treatment (Section 4.2.5), it was evident that the process failed to remove antigen fully
from the columns when concentrations greater than 1,050 pg/1 were assayed.
Therefore, another treatment would be required in this case.
Before one can measure samples using a developed assay, it is important that the assay
be validated, most importantly for accuracy and precision. Firstly, it is useful to test for
inconsistency in the analysis of standards, since any problems here will point to
potential deficiencies in the precision and, therefore, accuracy of sample analysis. The
resultant information may be represented graphically as a plot of coefficient of
variation (y-axis) against the standard analyte concentration (x-axis). This precision
profile allows one to determine the range of analyte concentrations that give acceptable
levels of imprecision, for example, C.V. <10%. Incorporated into this analysis is the
determination of the assay sensitivity, the operational definition being “the smallest
detectable dose at which the assay response is significantly different from zero”
(Micallef and Ahsan, 1994). This limit may be measured from the dose-response curve
by extrapolation from the y-axis at the signal equal to the background noise plus three
standard deviations (Brailly et al., 1994; Micallef and Ahsan, 1994).
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To determine the working range and the limit of detection of the present assay, ferritin
standards ranging from 4.1 to 525 |j,g/l, plus a blank, were assayed in replicates of five
(Section 4.3.2). Imprecision values obtained were less than 5% for all concentrations
tested, thus establishing the working range at 4.1 to 525 ng/l. The minimum detectable
dose was calculated as 0.7 |Lig/l, equivalent to 1.56 x 10'*^ mol/l or 3.11 x 10'^^ mol.
However, this was considered as only a potential sensitivity,

since ferritin

concentrations at this level were not assessed for (im)precision. Therefore, the
detection limit had to be set at 4.1 pig/l or 9.11 x 10'’^ mol/l (1.82 x 10’^^ mol). In any
case, there is little need to assay concentrations below 4.1 ng/1, since this is well below
the clinical decision limit for ferritin of 15 jig/1.
In addition, since it was intended to reuse the columns after assays, it was necessary to
assess how the regeneration process would affect the detection limit and assay
precision. The latter was of particular interest, since there was no guarantee that the
process would affect all the columns to the same degree. Such an occurrence would
inevitably lead to an increase in imprecision. However, results obtained for a further
nine assays using the same columns allayed this initial fear (Section 4.3.2). The
coefficients of variation for the standards rarely rose above 5%, indicating that the
regeneration process affected all the columns to equivalent degrees. Moreover, the
limit of detection remained at the subfemtomolar level throughout.
Although imprecision values obtained for standards over the ten assays were
impressive, one could not assume that serum samples would respond with such
consistency. Therefore, it was necessary to assess the within-run precision of serum
samples. For this purpose, three serum pools, representing different levels of the
working range, were assayed in replicates of ten using freshly prepared columns
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(Section 4.3.3 ). As expected, precision matched that of standards at each of the levels
tested. In addition, since the within-run precision of standards was maintained over
nine regeneration processes (ten assays), it was assumed that the same would be true
for the samples. In support of this assumption, favourable inter-assay precision values
were obtained when the three serum pools were analysed singly for a further nine
assays using the same columns (Section 4.3.4).
Standards for the present assay were prepared in a Tris-HCl buffer, pH 7.4, containing
0.1% BSA (w/v) and 0.035% Tween 20 (v/v). Due to obvious differences between the
standard matrix and that of serum samples, there was no guarantee that serum samples
would be measured accurately. The accuracy of the system was determined using
recovery, linearity, and correlation studies. For analytical recovery, human serum
devoid of ferritin was spiked with known amounts of ferritin standard and analysed
using the present assay on columns used once previously (Section 4.3.5). The recovery
values for the eight samples tested (5-480 pg/l) were 91-110%, with a mean of
101.9%, indicating that serum samples reacted with the system in the same way as
standards. This conclusion was strengthened further by results of the linearity studies
(Section 4.3.6). Three serum samples with high ferritin concentrations were diluted in
the standard matrix and the dilutions of each sample, together with the neat serum,
were assayed using freshly prepared columns. When the volume of sample was plotted
on the x-axis against the measured concentration on the y-axis for each sample, no
significant deviation from linearity was found. In addition, plotting the dilution (x-axis)
against specific absorbance (y-axis) for the standard and the samples gave a series of
parallel curves. However, according to Micallef and Ahsan (1994), the latter method
can hide even pronounced effects. Finally, the assay’s ability to measure serum samples
with accuracy was further highlighted by the results of the correlation study (Section
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4.3.7). The measured ferritin concentrations obtained for thirty clinical samples showed
excellent correlation (r == 0.995, y = 1.084x - 1.388) to results obtained using the
chemiluminescence immunoassay performed on the Ciba Corning ACS: 180.
The assay protocol includes an initial addition of a 3 ml volume of carrier buffer after
storage solution (approx. 2 ml of dH20) has drained completely from the columns.
However, this process is ONLY required when using columns directly from storage.
When columns are to be used immediately after regeneration, the equilibration step can
be excluded from the procedure, since the regeneration process leaves the columns
ready to receive sample or standard. Consequently, the time of sample analysis is
reduced slightly in such a case. The assay protocol also includes a lengthy 30-min
incubation step for the detection of the bound alkaline phosphatase label. To overcome
this limitation, one could use a substrate that is converted into a product detectable
with a high degree of sensitivity, e g., 4-methylumbelliferyl phosphate. Therefore, one
could use a shorter substrate incubation time to achieve the same assay sensitivity.
Alternatively, a label could be used that does not require an incubation step for its
detection, e g., fluorescent tag.
As a consequence, the final system permits the simultaneous measurement of up to
forty samples and nine standards in approximately 1.5 h, with the potential to process
up to 400 samples per day, if one allows approximately 60 min for the regeneration of
the columns after each batch. Such a sample throughput compares very favourably
with some of the flow-through systems described previously in Section 1.13. However,
for the measurement of a single sample (or very small numbers of samples) all of these
assays tend to be faster.
The HPIAC sandwich ELISA developed by de Alwis and Wilson (1985) requires only
approximately 15 min for the analysis of a single sample. Subsequent to determination,
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a further 15 min are required for immunoreactor regeneration and equilibration prior to
measurement of another sample. Therefore, when measuring a large batch of samples
one requires 30 min per analysis. For instance, to assay a batch of forty samples
continuously would take in the region of 20 h. According to Janis and Regnier (1989),
their DCIA has a similar sample throughput, requiring only 30 min per sample or 24 h
for forty to fifty. The HPIAC system designed by Hage and Kao (1991) for the
measurement of parathyroid hormone requires 1 h 6 min per sampling, allowing at least
1 h for pre-incubation of sample and labelled antibody and 6 min per plasma injection.
Despite this pre-incubation, the authors state that up to 240 samples may be analysed
per day. The flow-ELISA developed by Nilsson et al. (1993) permits the analysis of a
single sample in 330 s or up to 260 samples in 24 h, while the displacement flowinjection assay for cortisol designed by Kronkvist et al. (1997) requires about 8 min per
sampling, giving a daily throughput of approximately 180. Their competitive flowinjection assay has a sample throughput of twenty per hour, if one excludes the 1-h
incubation of sample and labelled antibody prior to injection. If the timing of these
incubations is staggered 3 min apart, one could potentially measure approximately 450
samples per day. The non-competitive ACMIA designed by Freytag et al. (1984) had a
total analysis time of 18 min, however, since the number of columns analysed
simultaneously was not stated, it is difficult to assess the sample throughput. In any
case, even if only ten samples were analysed together every 18 min, the sample
throughput would be thirty per hour or approximately 800 per day. However, by far
the fastest assay with the greatest sample throughput was developed by Cassidy et al.
in 1992. Using KICQA immunoassay, they were able to analyse samples for albumin in
under 1 min, giving a potential sample throughput of up to 1,440 per day.
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The detection limit of the present assay was set at 1.82 x 10"'^ mol, which is equivalent
to 4.1 M-g/l or 9.11 X lO'^^ mol/l when a 200 \i\ assay volume is used. Such sensitivity
compares very favourably with some of the flow-through immunoassays described
earlier (Section 1.13). The HPIAC immunoassay developed by de Alwis and Wilson
(1985) had the ability to measure 1 pmol of bovine IgG using a 30 pi volume (3.33 x
10'^ mol/l), while Janis and Regnier (1989) measured 0.7 pmol of transferrin in a 20 pi
volume (3.5 x 10'^ mol/l) using DCIA. The ACMIA designed by Freytag et al. (1984)
for digoxin and the KICQA immunoassay developed by Cassidy et al. for albumin
could measure 5.11 x lO'*' mol (2.56 x 10'^ mol/l) and 1.5 x lO'*"^ mol, respectively.
For Kronkvist et al. (1997), the best sensitivities were achieved when using the
competitive flow-injection immunoassay for budesonide, which allowed measurement
of 0.02 pmol (8 X 10'^ mol/l) using amperometric detection. However, in this case,
assessment with real samples (serum/plasma) was neglected While the sensitivities
quoted fail to match the sensitivity achieved by the flow-through system presented
here, others have succeeded in determining analytes at the attomolar level using
column-based systems. For example, the HPIAC assay for parathyroid hormone
designed by Hage and Kao (1991) measured as little as 16 amol in a 66 pi assay
volume (2.4 x 10'^^ mol/l), while Lejeune et al. (1990) measured as little as 0.1 amol of
human growth hormone using RACIA. It should be stated, however, that the latter
achieved such a sensitivity using standards prepared in buffer and using a 3.25-h
revelation time for the amplified assay of alkaline phosphatase activity. From a
calibration curve prepared using the same amplification procedure (Section 4.3.8), it
appeared that a 1 pg/1 sample could be measured with confidence using the present
assay, even after thirteen regenerations of the columns. In addition, the sample volume
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used was only 50 |ul, giving approximately a 16-fold increase in sensitivity (1.82 x 10'^^
mol v’s ~1.11 X 10'^^ mol) in the same assay time.
An attractive feature of the present assay system is that the columns can be regenerated
using a low pH buffer. This presents a deviation from the conventional immunoassay
system where the solid phase tends to be used only once. However, such a disregard
for economy seems foolish, since more than ten immunoassay cycles can be realised
with the same antibody-coated microtitre plates (Ilchmann et al., 1990). Similarly, at
least ten assays can be performed with the same columns without apparent adverse
affects to the reliability and sensitivity of the system. However, there is no reason to
doubt that a far greater number of assays could be performed, since both de Alwis and
Wilson (1985) and Janis and Regnier (1989) were able to use their immunoreactors for
at least 500 assays using similar elution buffers. Similarly, Hage and Kao (1991)
achieved 200-250 injections per column, while Nilsson et al. (1994) were able to
perform fifty assays, and in some cases several hundred assays, using the same
immunoreactor. However, the system adopted by Kronkvist et al. (1997) potentially
allows the immunoreactor to be reused for even more assays, since the columns do not
require regeneration after each assay. Moreover, the enzyme-substrate reaction is
carried out in a post-column reactor, thus the immunochemical equilibrium of the
column is not disturbed by the substrate buffer used.
In conclusion, the affmity-column-mediated ELISA described here is suitable for use in
the determination of ferritin in serum samples with concentrations below, within, and
above the clinical decision limits. The assay shows a level of reliability and sensitivity
comparable to the flow-through systems presented in the literature. The sensitivity,
however, is far lower than that achieved elsewhere for ferritin determination using
conventional immunoassay (Ishikawa et al., 1982; Hashida and Ishikawa, 1990). The
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sample throughput of approximately 400 per day is higher than most of the flow
through systems described, however, for the analysis of a single sample or a small
number of samples the latter are superior. In addition, since no lengthy incubations are
required for reaction of antigen with its specific antibodies, the overall analysis time
tends to be faster than conventional systems. However, the sample throughput of the
latter can be well over 1,000 per day, especially if microtitre plate technology is used
with automation. In addition, the same columns can be used over ten assays without
affecting the integrity of the columns. Presumably, the columns could be used a greater
number of times. Finally, the procedure is simple and can be potentially applied to the
measurement of any analyte measurable through conventional immunoassay.
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7 Appendix

7 Appendix

7.1 Affinity-Column-Mediated Flow-Through ELISA for Ferritin

7.1.1 Summary and explanation of assay
The principles of affinity chromatography and two-site sandwich immunoassay are
combined to produce a system capable of rapid (~ 1.5 h) and sensitive quantitation of
ferritin in serum. In the assay, samples and standards are passed through separate
columns containing immobilised

anti-ferritin antibody,

and bound

antigen

is

subsequently detected using an anti-ferritin-alkaline phosphatase conjugate. To detect
immobilised label, substrate solution is added and product is developed in the column
at room temperature. Following elution of product from the column, the absorbance is
measured and the columns are regenerated using a low pH elution.

7.1.2 Materials required
a) Carrier buffer; 50 mmol/1 Tris-HCl, pH 7.4, containing 0.5 mol/l NaCl, 0.1% (w/v)
BSA and 0.035% (v/v) Tween 20.
b) Substrate buffer: 0.1 mol/l Tris-HCl, pH 9.8, containing 1.5 mol/l NaCl.
c) Regeneration buffer: 0.1 mol/l glycine-HCl, pH 2.1.
d) Ferritin from human liver.
e) Mouse monoclonal IgG to human ferritin (Clone B8, Biomerieux, Lyon, France).
f) Monoclonal

anti-human

ferritin-alkaline

Biomerieux, Lyon, France).
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phosphatase

conjugate

(Clone

B8,

g) Immunoaffinity columns: Polystyrene columns (0.5-2.0 ml) packed with cyanogen
bromide-activated Sepharose 4B (0.5 ml), to which anti-ferritin antibody has been
coupled (500 jig/g)
h) /?-Nitrophenyl phosphate (/?NPP).

7.1.3 Test procedures

7.1.3.1 Using the immunoaffinity column
1.

To use the column, remove the top cap first. This prevents bubbles being drawn
into the gel. Next, remove the bottom cap and place the column in a suitable
holder, e.g., 16 x 150 mm test tube. Allow the storage solution (approx. 2 ml of
dH20) to drain completely from the column.

2.

If air bubbles are entrapped in the gel, spin the column first at 1,000 g for 10 min.
This procedure is important, since air bubbles significantly reduce flow rates.

7.1.3.2 Quantitation offerritin
1.

Equilibrate'^ all columns with at least 3 ml of carrier buffer.

2.

Pipette 200 pi of standards (ferritin dissolved in carrier buffer) or samples into
separate columns and allow them to pass through under gravity. Add 500 pi of
carrier buffer to each column to wash antigen further into the gel.

3.

Pass 500 pi of the anti-ferritin-alkaline phosphatase conjugate diluted in carrier
buffer (1.96 pg/ml) through each column.

4.

Wash the excess through using 1 + 1 ml of carrier buffer.

'' Equilibration is only required when using columns directly from storage.
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5.

Add 500 III of substrate solution (2 mg of pNPP per ml of substrate buffer) to
each column and incubate at room temperature for 30 min. The timing of substrate
incubation should be started upon addition of substrate to the first column

6.

Transfer the columns to clean test tubes (10 x 100 mm) and elute /?-nitrophenol
(pNP) product using 1 ml of carrier buffer. To ensure that the timing of incubation
of substrate within each column is precise, elution buffer should be added to the
batch of columns in the same sequence as the addition of substrate. Therefore, if
one assumes that the speed of pipetting substrate approximates the speed of
pipetting elution buffer, the time of incubation of substrate should be the same
within each column.

7.

Pipette 100 \x\ of the eluate in each tube to a microtitre well and read their
absorbances at 405 nm.

8.

To regenerate the columns, add 1 ml of regeneration buffer, followed by 2 ml of
carrier buffer. Repeat this cycle two more times.
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